

CURRICULUM VITAE

Date of Revision: 02/13/2020

Name: Steven D. Gore, M.D.

Primary Appointment: Professor, Department of Internal Medicine, Section of Hematology, Clinician Educator Track

Term: On a continuing basis beginning July 1, 2015

School: Yale University School of Medicine

Education:

B.S. Yale University, (Biology) 1978
M.Phil. Yale University School of Medicine (Pharmacology) 1984
M.D. Yale University School of Medicine 1984

Career/Academic Appointments:

1984-85 Intern, Internal Medicine, University of Chicago Hospitals and Clinics, Chicago, IL
1985-87 Resident, Internal Medicine, University of Chicago Hospitals and Clinics, Chicago, IL
1987-88 Senior Clinical Fellow in Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD
1987-88 Clinical/Research Fellow in Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD
1990-91 Instructor in Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD
1991-97 Assistant Professor of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD
1997-08 Associate Professor of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD
2008-13 Professor of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD
2013-present Staff Attending Physician, Yale New Haven Hospital, New Haven, CT Clinician, Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT
2014-present Professor of Medicine (Hematology), Yale School of Medicine

Administrative Positions:

2013-present Director of Hematologic Malignancies, Yale Cancer Center, New Haven, CT

Board Certification (Grandfathered for Recertification):

American Board of Internal Medicine, Internal Medicine, 1987
American Board of Medical Oncology, Medical Oncology, 1989

Professional Honors & Recognition:

International/National/Regional

2010: National Institutes of Health Award of Merit for Service on Physicians Data Query Editorial Board
2004: Stohlman Scholar of Leukemia & Lymphoma Society of America
1998-03: Leukemia Society of America, Scholar Award in Clinical Research
1992-95: American Cancer Society, Career Development Award
1991-92: American Society of Clinical Oncology, Young Investigator Award
1987-88: American Cancer Society, Clinical Fellow

University

1978-82: Medical Scientist Training Program, Yale University
1978: Summa Cum Laude, Yale University
1978: Edgar Boell Prize in Biology, Yale University
1977: Phi Beta Kappa

Grant/Clinical Trials History:

Current Grants:

Agency: NIH NHLBI (subcontract with Univ. of Miami)
I.D.#: 1R01HL126947-01 (Figueroa, ME)
Title: "Epigenetic biomarkers of response to Azacytidine in Myelodysplastic Syndromes"
PI: Steven D. Gore, M.D.
Percent effort: 3%
Direct costs per year: \$191,475
Project period: 05/01/2015-04/31/2020

Current Clinical Trials:

Agency: Pfizer
I.D.#: NCT02367456 (HIC#1410014839, Sponsor Protocol # B1371012)
Title: A Combination Study of PF-04449913 and Azacitidine in First Line MDS, AML and CMML Patients
PI: Steven D. Gore, M.D.
Project period: Protocol opened 3/01/15-10/30/2016 (anticipated)

Past Grants:

Agency: NIH
I.D.#: K24 CA111717-06A1
Title: Targeting Epigenomics in Myeloid Neoplasms
PI: Steven D. Gore, M.D.
Role: PI
Direct costs per year: \$182,301
Total costs for project period: \$985,285
Project period: 12/01/2004 – 06/30/2017

Agency: The Leukemia & Lymphoma Society
I.D.#: 6316-11
Title: Epigenetically targeted drugs and leukemia progenitor cells
PI: Steven Gore, M.D.
Role: PI
Percent effort: 10%

Direct costs per year: \$180,018
Total costs for project period: \$600,000
Project period: 12/01/2010 – 09/30/2014

Agency: NIH
I.D.#: U10CA016116
Title: Eastern Cooperative Oncology Group
PI: Steven Gore, M.D.
Role: PI
Percent effort: 2%
Direct costs per year: \$166,865
Total costs for project period: \$1,022,624
Project period: 05/01/2010 – 11/01/2013

Agency: Edward P. Evans Foundation to the Aplastic Anemia
I.D.#: MDS International Foundation (AA&MDSI)
Title: MDS Clinical Research Consortium
PI: Steven Gore, M.D.
Role: PI
Percent effort: 10%
Direct costs per year: \$300,000
Total costs for project period: 1,500,000
Project period: 12/01/2012 – 11/01/2013

Agency: NIH ARRA
I.D.#: 1RC1CA145831
Title: Use of Erythropoietin Stimulating Agents, Outcomes, and Cost of Care among Elderly Patients with Myelodysplastic Syndrome
PI: Steven Gore, M.D.
Role: PI
Percent effort: 10%
Direct costs per year: \$34,880
Total costs for project period: \$2,043,750
Project period: 09/30/2009 - 09/29/2011

Agency: The Leukemia & Lymphoma Society
I.D.#: R6034-08
Title: Epigenetically targeted drugs and leukemia progenitor cells". The goals of this project are to Examine the impact of drugs which target the epigenome on leukemia progenitor cells in vitro and in vivo.
PI: Steven Gore, M.D.
Role: PI
Percent effort: 50%
Direct costs per year: \$180,018
Total costs for project period: \$400,000
Project period: 10/01/2007 – 09/30 2010

Agency: NIH
I.D.#: R01 CA 100904-01

Title: Arsenic Trioxide in Primary Curative APL Therapy
PI: Steven Gore, M.D.
Role: PI
Percent effort: 20%
Direct costs per year: \$356,013 (Final Year)
Total costs for project period: \$2,316,476
Project period: 07/01/2004 – 06/30/2010

Agency: NIH
I.D.#: R01 CA125563501
Title: Mechanism of combined ‘epigenetic therapy’ in myeloid malignancies
Percent effort: 10%
Direct costs per year: \$420,489 (Last Year)
Total costs for project period: \$1,483,863
Project period: 09/01/2007 – 07/31/2010

Agency: Leukemia and lymphoma Society of America
I.D.#: 6040-05
Title: MS-275 and 5-Azacytidine in Myeloid Malignancies
PI: Steven Gore, M.D.
Role: PI
Percent effort: 10%
Direct costs per year: \$120,370
Total costs for project period: \$390,000
Project period: 10/01/2004 – 09/30/2007

Agency: NIH
I.D.#: 1 R21 CA110507-01/Quick Trials
Title: 5-Azacytidine and MS-275 in Myeloid Malignancies
PI: Steven Gore, M.D.
Role: PI
Percent effort: 10%
Direct costs per year: \$184,500
Total costs for project period: \$543,257
Project period: 07/01/2004 – 06/30/2006

Agency: Samuel Waxman Cancer Research Foundation
Title: Optimizing Therapies Based in Inhibition of DNA Methylation and Histone Deacetylation
Role: Co-Investigator
Percent effort: 5%
Project period: 01/01/2002 – 12/31/2004

Past Clinical Trials

Agency: Karyopharm
I.D.#: KCP-330-008 (HIC# 1411014855)
Title: A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear

Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients
≥ 60 Years Old with Relapsed/Refractory AML Who Are Ineligible for Intensive
Chemotherapy and/or Transplantation

PI: Steven D. Gore, M.D.
Role: PI
Project period: 8/4/14- 8/4/2016

Agency: MEI Pharmaceuticals
I.D.#: MEI-005 (HIC# 1404013769)
Title: A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a
Hypomethylating Agent (HMA) in Patients with Myelodysplastic Syndrome
(MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone

PI: Steven D. Gore, M.D.
Role: PI
Project period: 5/12/14- 3/1/15

Agency: Celgene Corporation
I.D.#: RV-MDS-PI-295 (Clinical Trial)
Title: Phase II Trial of High Dose Lenalidomide in Patients with MDS and AML with
Trilineage Dysplasia (AML-TLD)

PI: Steven Gore, M.D.
Role: PI
Percent effort: 5%
Direct costs per year: \$280,448
Total costs for project period: \$375,800
Project period: 10/01/2008 – 11/01/2014

Agency: Onconova Therapeutics, Inc.
I.D.#: 11100
Title: A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and
Safety of ON01919.NA Administered as a 72-Hour Continuous Intravenous
Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess
Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine

PI: Steven Gore, M.D.
Role: PI
Percent effort: 1%
Direct costs per year: \$108,431
Total costs for project period: \$167,707
Project period: 06/01/2011 – 10/31/2013

Agency: Eli Lilly and Co
I.D.#: H8K-MC-JZAJ
Title: A phase 1 study of LY573636-sodium in patients with relapsed or refractory acute
myeloid Leukemia” (Protocol H8K-MC-JZAJ)

PI: Steven Gore, M.D.
Role: PI
Percent effort: 1%
Direct costs per year: \$90,782
Project period: 04/14/2011 - 04/14/2013

Agency: Pharmion/Celgene Corporation
I.D.#: 102699
Title: A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Dose of Azacitidine
PI: Steven D. Gore, M.D.
Role: PI
Percent effort: 5%
Direct costs per year: \$364,331
Total costs for project period: \$488,204
Project period: 01/31/2008 – 01/31/2013

Agency: GlaxoSmithKline
I.D.#: GSK059
Title: Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS
PI: Steven Gore, M.D.
Role: PI
Percent effort: 1%
Direct costs per year: \$91,738
Project period: 05/05/2010 – 11/02/2012

Agency: Cell Therapeutics, Inc.
I.D.#:
Title: A Pilot Study of Trisenox (arsenic trioxide) Based Consolidation Therapy for Primary Treatment of APL
PI: Steven Gore, M.D.
Role: PI
Percent effort: 5%
Direct costs per year: \$38,499
Project period: 11/01/2003 – 10/31/2006

Agency: Celgene
I.D.#: CC-5013-MDS-002
Title: Open Label Phase II Trial of CC5013 in Low Risk MDS Patients without Deletions of Chromosome 5Q
PI: Steven Gore, M.D.
Role: PI
Percent effort: 5%
Direct costs per year: \$131,837
Project period: 22/01/2003 – 10/31/2005

Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale:

International/National

2019: Invited Talk, Advanced Science Workshop on Myeloproliferative Disorders. New Haven,

- CT. October 2019. “Management of Higher Risk MDS and CMML.”
- 2019: 9th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy. Litchfield Park, Arizona. Moderator: “Targeting the Epigenome”.
- 2018: ECOG-ACRIN Cancer Research Group Fall 2018 Meeting. Fort Lauderdale, FL. “Randomized Phase II for Poor Risk AML.”
- 2018: University of Miami Leukemia Symposium. Miami, FL.
- 2018: Romanian Society of Hematology Annual Meeting, Sinaia, Romania. “Management of Myelodysplastic Syndromes.”
- 2018: The National Myelodysplastic Syndromes Natural History Study (MDS) Steering Committee Meeting. Rockville, MD.
- 2017: University of Chicago External Advisory Board Committee Meeting. Chicago, IL.
- 2016: Oncology Translational Research Conference, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD. “Epigenetic Therapy 15 years later: What have we done? What are we doing?”
- 2016: Epigenetic Regulation of Normal Hematopoiesis and its Dysregulation in Myeloid Neoplasia – 6th Annual Symposium, Villa Vigoni, Lovenjo di Menaggio, Italy. “Epigenetic Therapy 15 Years Later: What have We Done? What are We Doing?” May 2016.
- 2015: Society of Hematologic Oncology Annual Meeting. “Debate: Resolved, Azanucleoside Combinations with Histone Deacetylase Inhibitors are dead. Negative Position.”
- 2015: Department of Hematology, Queens University, Kingston, Ontario, Canada. Epigenetic Therapy” 15 years later: What have we done? What are we doing?”
- 2015: Princess Margaret Cancer Center, Toronto, Ontario, Canada Hematology Grand Rounds. “Epigenetic Therapy” 15 years later: What have we done? What are we doing?”
- 2015: Sunnybrook Health Science Center, Toronto, Ontario, Canada “Epigenetic Therapy 15 years later: What have we done? What are we doing?”
- 2015: McMaster University, Hamilton, Ontario, Canada- Hematology lecture. “Epigenetic Therapy- 15 years later: what have we done? Where are we going?”
- 2015: Edward P. Evans Foundation MDS Summit 2015
- 2014: University of Freiburg, Freiburg, Germany. “Differentiating and Starting to Proliferate: Moving towards *Targeted* “epigenetically-targeted” drugs in Hematologic Malignancies.”
- 2014: Celgene Pharmaceutical, Summit Park, NJ. “Epigenetic Therapy” 15 years later: What have we done? What are we doing?”
- 2014: Hematology/Oncology Grand Rounds, University of Massachusetts School of Medicine, Worcester, MA. “Epigenetic Therapy” 15 years later: What have we done? What are we doing?”
- 2013: The Merrill J. Egorin Workshop in Cancer Pharmacology (speaker), Leesburg, VA, “Epigenetic as a Therapeutic Approach – HDAC Inhibitors”
- 2013: Hematology Grand Rounds, Northwestern University, Chicago, IL, “Alfred Stopcock Presents the Very Strange Case of the Mysterious Activity of the Failed Antileukemia Azanucleosides”
- 2013: Hematology Grand Rounds, Northwestern University, Chicago, IL, “Alfred Stopcock Presents The Very Strange Case of the Mysterious Activity of the Failed Antileukemia Azanucleosides”
- 2012: The Merrill J. Egorin Workshop in Cancer Pharmacology (speaker), Leesburg, VA, “Epigenetics as a Therapeutic Approach – HDAC Inhibitors”
- 2012: Patient Forum, Aplastic Anemia and MDS Foundation, Fred Hutchinson Cancer Research Center, Seattle, WA

- 2012: Food and Drug Administration, Silver Spring, MD, “Mechanism behind Epigenetically Targeted Drugs”
- 2011: The Merrill J. Egorin Workshop in Cancer Pharmacology, Leesburg, VA, “Epigenetics as a Therapeutic Approach – HDAC Inhibitors”
- 2011: State of the Science Symposium: Myelodysplastic Syndrome (MDS), Bethesda, MD, “Using Epigenetically Targeted Drugs to Treat Cancer”
- 2011: National Institutes of Health, Baltimore, MD, “Using Epigenetically Targeted Drugs to Treat Cancer. Translating Epigenomic Discoveries into Improvements in Human Health”
- 2011: American Society Clinical Pharmacology Therapeutics Meeting, Dallas, TX “Targeting Epigenetic Changes in Cancer Therapeutics”
- 2011: Grand Rounds, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, NJ, “Targeting Epigenetic Changes in Cancer Therapeutics”
- 2010: Aplastic Anemia & MDS International Foundation, Newark, NJ, “Treating Higher-Risk MDS”
- 2010: Vanderbilt/Nashville Visiting Professor Speaker, Nashville, TN, “Targeting Epigenetic Changes in Cancer Therapeutics”
- 2010: Invited Speaker and Session Chair, National Institute of Child Health and Human Development, Bethesda, MD, “Epigenetic Basis of Intellectual and Developmental Disabilities (IDD): From Etiologic Discovery to Therapeutic Interventions”
- 2010: MDS Symposium, University of Minnesota, Minneapolis, MN, Development of Epigenetic Drugs for the Treatment of MDS”
- 2010: Pharmacology Workshop, Leesburg, VA, “Epigenetics as a Therapeutic Approach – HDAC Inhibitors”
- 2010: 15th Congress of European Hematology Association, Barcelona, Spain, “Misreading the Genome: Epigenomics and Leukemia”
- 2010: Bone Marrow Failure Disease Scientific Symposium, Aplastic Anemia and MDS Foundation, Bethesda, MD, Invited Speaker
- 2009: Ohio State Comprehensive Cancer Center, Columbus, OH, “New Paradigms in MDS”
- 2009: 10th International Symposium on MDS, Patras, Greece, “Optimizing Combination Strategies”
- 2009: Houston Marriott Medical Center, Houston, TX, “Activity in Search of Mechanism: How Do ‘Epigenetic therapies’ Work in Myelodysplastic Syndrome?”
- 2009: Leukemia and Lymphoma Society, Hershey, PA, “Changing Gene Expression to Treat Leukemia”
- 2009: Tawam Hospital, Oncology Visit, Dubai, United Arab Emirates, “Case Discussions”
- 2009: Roswell Park Cancer Institute, Buffalo, NY, “Cajoling Cancer or Cytotoxicity Redux: How Do Epigenetically-Targeted Drugs Work in Hematologic Malignancies?”
- 2009: Epigenetics 2011 Organized Workshop, Coral Gables, FL, “DNMT Inhibitors as DNA Damaging Agents”
- 2008: Lutheran Medical Center, Brooklyn, NY, “Advances in the Management of Myelodysplastic”
- 2008: EHA 13th Congress of the European Hematology Association, Copenhagen, Denmark, “Defining the Rose of Epigenetic Therapy in Myelodysplastic Syndromes”
- 2008: American Association for Cancer Research, Boston, MA, “Combined DNA Methyltransferase and Histone Deacetylase Inhibition for the Treatment of Hematologic Malignancies: Which, When, Why?”
- 2008: Vanderbilt University, Nashville, TN, “Epigenetic Therapy for Hematologic Malignancy: Searching for the Mechanism”
- 2008: University of Alabama, Birmingham, AL, “Cajoling Cancer or Cytotoxicity Redux: How do

- Epigenetically-Targeted Drugs Work in Hematologic Malignancies?”
- 2008: University of Texas, MD Anderson, Houston, TX, “Cajoling Cancer or Cytotoxicity Redux: How Do Epigenetically-Targeted Drugs Work in Hematologic Malignancies?”
- 2008: Wistar Institute, Philadelphia, PA, “Cajoling Cancer or Cytotoxicity Redux: How do Epigenetically-Targeted Drugs Work in Hematologic Malignancies?”
- 2007: Duke University, Durham, NC, “Making Sense of Myelodysplastic Syndromes: From Diagnosis to Treatment”
- 2007: 2007 Workshop of Society for Hematopathology/European Association for Haematopathology, Indianapolis, IN, “Biologically Rational Approaches to Myelodysplastic Syndromes”
- 2007: NCCN 12th Annual Conference, Hollywood, FL, “Advances in the Treatment of Myelodysplasia and Thrombocytopenia”
- 2007: Grand Rounds, New York School of Medicine, New York, NY, “Moving Beyond the First Generation of Therapies Targeting Epigenetic Changes in Hematologic Malignancies”
- 2007: American Association for Cancer Research, San Francisco, CA, “Epigenetic Therapies – What’s the Target?”
- 2007: Grand Rounds, University of Kentucky, Lexington, KY, “Myelodysplastic Syndromes: Therapeutic ‘Light’ at the End of the Tunnel”
- 2007: University of Kentucky, Lexington, KY, “Current Treatments for MDS”
- 2007: American Society of Hematology (ASH) State of the Art Symposium, Philadelphia, PA, “Myelodysplastic Syndromes: Therapeutic ‘Light’ at the End of the Tunnel”
- 2007: 2007 Fall CTEP Early Drug Development Meeting, Bethesda, MD, “Development of the Combination of 5-azacitidine Plus SNDX-275 (formerly MS-275) in Myeloid Malignancies”
- 2007: Fox Chase Cancer Center, Philadelphia, PA, “Making Sense of Myelosysplastic Syndromes: From Diagnosis to Treatment”
- 2007: The XXIII Symposium of the International Association for Comparative Research on Leukemia and Related Diseases, Freiburg, Germany, “Emerging Treatment Options in High Risk Myelodysplastic Syndrome”
- 2007: Aplastic Anemia & MDS Foundation Patient & Family Conference, Las Vegas, NV, “Myelodysplastic Syndrome”
- 2007: Hematology Grand Rounds, Temple University, Philadelphia, PA, “Moving Beyond the First Generation of Epigenetic Therapies in Hematologic Malignancies”
- 2007: 9th International Symposium on Myelodysplastic Syndromes, Florence, Italy, “Evidence-based Treatment of Myelodysplastic Syndromes”
- 2007: National Comprehensive Cancer Network 12th Annual Conference, Hollywood, FL, “Advances in the Treatment of Myelodysplasia and Thrombocytopenia”
- 2007: European Hematology Association Epigenetics Meeting, Mandelieu, France, “Avoiding Tunnel Vision: Do Current Therapies Targeting Epigenetics Work Through Epigenetic Mechanisms?”
- 2006: Spotlight Symposium, Annual Meeting of the American Society of Hematology, Orlando, FL, “Spotlight on New Agents in Myelodysplasia”
- 2006: Satellite Symposium, American Society of Hematology, Orlando, FL, “Future Applications and Directions for Translational Therapies: The Promise of Epigenetic Therapy”
- 2006: The 11th International Conference on Differentiation Therapy and Innovative Therapeutics in Oncology “Apoptosis, Differentiation, Signaling, Epigenetics and Beyond”, Versailles, France, “Avoiding Tunnel Vision: Do Current Therapies Targeting Epigenetics Work Through Epigenetic Mechanisms?”
- 2006: Modern Trends in Oncology with Stem Cells and Targeted Therapy, Arlington Cancer Center, Arlington, TX, “Towards Biologically Rational Therapies for the Treatment of

- Myelodysplastic Syndrome”
- 2006: National Comprehensive Cancer Network, Hematologic Malignancies Congress, New York, NY, “Treatment by Risk Groups and the Role of High-Intensity Therapy”
- 2006: University of Chicago, Chicago, IL, “Moving Beyond the First Generation of Therapies Targeting Epigenetic Changes in Hematologic Malignancies”
- 2006: Hawaii Society of Clinical Oncology, Honolulu, HI, “Towards Biologically Rational Therapies for the Treatment of Myelodysplastic Syndrome”
- 2006: Virginia Mason Cancer Center, Seattle, WA, “Towards Biologically Rational Therapies for the Treatment of Myelodysplastic Syndrome”
- 2006: Fred Hutchinson Cancer Research Center, Seattle, WA, “Moving Beyond the First Generation of Therapies Targeting Epigenetic Changes in Hematologic Malignancies”
- 2006: The University of Texas MD Anderson Cancer Center MDS Symposium, Invited Participant, Houston, TX, “Moving Beyond the First Generation of ‘Epigenetic Therapies’ in Myelodysplastic Syndromes”
- 2006: Dartmouth University School of Medicine, Lebanon, NH, “Moving Beyond the First Generation of Therapies Targeting Epigenetic Changes in Hematologic Malignancies”
- 2006: National Cancer Center Network Annual Meeting, Westin Diplomat, Hollywood, FL, “New Trends in the Management of Myelodysplastic Syndromes”
- 2006: Sarah Cannon Cancer Center, Nashville, TN, “Towards Biologically Rational Therapy for Myelodysplasia”
- 2006: Rush University Medical Center, Chicago, IL, “Towards Biologically Rational Therapy for Myelodysplasia”
- 2006: University of Illinois, Chicago, IL, “Towards Biologically Rational Therapy for Myelodysplasia”
- 2005: University of California Los Angeles, Los Angeles, CA, “Emerging Treatments in Myelodysplastic Syndromes”
- 2005: University of Arizona, Arizona Cancer Center, Tucson, AZ, “Moving Beyond the First Generation of Therapies Targeting Epigenetic Changes in Hematologic Malignancies”
- 2005: University of Florida, Gainesville, FL, “Moving Beyond the First Generation Targeting Epigenetic Changes in Hematologic Malignancies”
- 2005: University of Illinois Medical Center, Chicago, IL, “Moving Beyond the First Generation Targeting Epigenetic Changes in Hematologic Malignancies”
- 2005: Satellite Symposium, European Hematology Association, Stockholm, Sweden, “Reversing DNA Methylation: The Basis for New MDS Therapies”
- 2005: 41st Annual Meeting, American Society of Clinical Oncology, Scientific Discussion, Poster Discussion Series, Orlando, FL, “Advances in Therapies Targeting Epigenetic Changes in MDS and AML”
- 2005: Dana Farber/Brigham and Women’s Cancer Center, Boston, MA, “Targeting Epigenetic Changes in Hematologic Malignancies”
- 2005: University of Wisconsin Comprehensive Cancer Center, Madison, WI, “Moving Beyond the First Generation of Therapies Targeting Epigenetic Changes in Hematologic Malignancies”
- 2005: Symposium in Epigenetics Reprogramming of Cancer Cells, American Society of Pharmacology and Experimental Therapeutics, San Diego, CA, “Clinical Application of Epigenetics in Cancer Therapeutics”
- 2005: Roswell Park Cancer Institute, Buffalo, NY, “Moving Beyond the First Generation of Epigenetic Therapies in Hematologic Malignancies”
- 2004: Myelodysplastic Syndrome Foundation Satellite Symposium, American Society of Hematology, San Diego, CA, “Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacididine and Sodium Phenylbutrate”

- 2004: Leukemia & Lymphoma Society, Stohlman Scholar Symposium, Denver, CO, “Reversing DNA Methylation: The Basis for the New MDS Therapies”
- 2004: Myelodysplasia 2004: 2nd Annual Symposium on Hematologic Malignancies, The Blood and Marrow Transplant Group of Georgia at Northside Hospital, Charleston, SC, “Myelodysplasia 2004”
- 2004: University of Kentucky, Lexington, KY, “Altering Form for Function: Targeting Epigenomics in Hematologic Malignancies”
- 2004: Vanderbilt University, Nashville, TN, “Altering Form for Function: Targeting Epigenomics in Hematologic Malignancies”
- 2004: Understanding DNA Methylation and Epigenetic Gene Silencing in Cancer, Satellite Symposium, American Society of Clinical Oncology, New Orleans, LA, “Clinical Relevance: Current and Emerging Therapeutic Applications”
- 2004: University of Pennsylvania Health System Cancer Center’s Hematologic Malignancies Retreat, Philadelphia, PA, “Altering Form for Function: Targeting Epigenomics in Hematologic Malignancies”
- 2004: Brigham & Women’s Hospital, Boston, MA, “Altering Form for Function: Targeting Epigenomics in Hematologic Malignancies”
- 2004: Grand Rounds, Northwestern University, Chicago, IL, “Altering Form for Function: Targeting Epigenomics for the Treatment of Myeloid Malignancies”
- 2003: Evolution in Current and Novel Therapies in MDS, American Society of Hematology Satellite Symposium, San Diego, CA, “Chromatin Remodeling: Altering Form for Function”
- 2003: Patient Symposium, Aplastic Anemia and Myelodysplastic Syndromes Foundation, San Francisco, CA, “The Future of Treatment for Myelodysplastic Syndrome”
- 2003: First Annual Conference: Targeted Therapies for the Treatment of Hematological Malignancies, Kona, HI, “Targeting Epigenomics in Hematologic Malignancies”
- 2003: Grand Rounds, MD Anderson Cancer Center, Houston, TX, “Epigenomics in Leukemia”
- 2003: 7th International Symposium on Myelodysplastic Syndrome, Paris, France, “New Approaches to the Treatment of Myelosplastic Syndromes: Epigenomics and Differentiation Therapy”
- 2003: University of Colorado Mini-Symposium on “DNA Repair and DNA Methylation”, University of Colorado, Denver, CO, “Methylation and Histone Modifications as Targets in Leukemia”
- 2003: National Cancer Institute Phase 1 Meeting, Bethesda, MD, “State of Translation of Epigenetics in Cancer Therapeutics”
- 2003: 2003 Tandem Bone Marrow Transplant Meeting, Boulder, CO, “Management of Bone Marrow Failure in Myelodysplastic Syndromes”
- 2002: Scientific Subcommittee on Neoplasia, American Society of Hematology, Philadelphia, PA, “Targeting Epigenetic Changes in Leukemia”
- 2002: Hematology Grand Rounds, New York University, New York, NY, “Targeting Epigenetic Changes in Leukemia”
- 2002: Hematology/Oncology Seminar Series, Vanderbilt University, Nashville, TN, “Epigenetic Changes as Therapeutic Targets in Myeloid Malignancies”
- 2002: Waxman Foundation Seminars, Mount Sinai Medical Center, New York, NY, “Valproic Acid as a Histone Deacetylase Inhibitor”
- 2001: 6th International Symposium on Myelodysplastic Syndromes, Stockholm, Sweden, “New Drugs in MDS”
- 2001: Visiting Professor, University of Chicago, Chicago, IL, “A Tale of Two Leukemias: Modifying Histones to Tame Cancer”
- 2001: Hematology Grand Rounds, Mount Sinai Medical Center, New York, NY, “Development of

Histone Deacetylase Inhibitors in Myeloid Malignancies”

- 2000: National Cancer Institute State of the Science Meeting for Myelodysplastic Syndromes, Bethesda, MD, “Developing Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in MDS”

Regional

- 2014: The University of Massachusetts, Worcester, MA. Hematology Grand Rounds. “Epigenetic Therapy” 15 years later: What have we done? What are we doing?”
- 2010: The George Washington University Medical Center, Washington, DC, “Myelodysplasia”
- 2008: CME, Frederick, MD, “Myelodysplastic Syndromes (MDS)”
- 2008: Baltimore Blood Club, Baltimore, MD, “Towards Biologically Rational Treatment for Myelodysplastic Syndromes”
- 2007: Leukemia & Lymphoma Society, Washington, DC, “Current Research and Emerging Treatments of Myelodysplastic Syndromes”
- 2007: Hematologic Malignancies Symposium, The Johns Hopkins University, Baltimore, MD, “Towards Biologically Rational Treatment for Myelodysplastic Syndromes”
- 2007: Oncology Grand Rounds, George Washington University Hospital, Washington, DC, “Moving Beyond the First Generation of Epigenetic Therapies in Hematologic Malignancies”
- 2006: Washington Hospital Center, Washington, DC, “MDS: Current Treatment Approaches and New Agents on the Horizon”
- 2006: Leukemia and Lymphomas Society of Maryland Patient Forum, Baltimore, MD, “Treatment Advances for Myelodysplastic Syndrome and Acute Myelogenous Leukemia”
- 2006: Updates in the Treatment of MDS, Baltimore, MD, “Targeting Epigenetic Changes for the Treatment of Myelodysplastic Syndrome: New Frontiers in the Treatment of Myelodysplasia”
- 2006: Fairfax INOVA Hospital, Alexandria, VA, “Myelodysplasia”
- 2005: Aplastic Anemia & MDS International Foundation, Montgomery General Hospital Grand Rounds, Olney, MD, “MDS 2005”
- 2005: Greater Baltimore Medical Center, Baltimore, MD, “Myelodysplastic Syndrome 2005: New Paradigms for Patient-specific Therapy Selection”
- 2005: St. Agnes Hospital, Baltimore, MD, “Myelodysplastic Syndrome 2005: New Paradigms for Patient-specific Therapy Selection”
- 2004: Hematology Fellowship Conference, National Heart Lung & Blood Institute, Bethesda, MD, “Altering Form for Function: Targeting Epigenetic Changes in Myeloid Malignancies”
- 2002: National Anemia Action Council Preceptorship on Hematologic Malignancies, Baltimore, MD, “Myelodysplastic Syndromes”
- 2000: Annual course in Hematology Malignancies and Bone Marrow Transplantation, Johns Hopkins University, Baltimore, MD, “Gene Re-expression as a Potential New Therapeutic Modality in Myeloid Malignancies”
- 1999: Grand Rounds, St. Agnes Hospital, Baltimore, MD, “Myelodysplastic Syndromes”
- 1999: Oncology Grand Rounds, Johns Hopkins University, Baltimore, MD, “Acute Promyelocytic Leukemia”
- 1999: Medicine Grand Rounds, Harbor Hospital, Baltimore, MD, “Myelodysplastic Syndromes”

Professional Service

Peer Review Groups/Grant Study Sections:

- 2017-present: Co-chair, NCI Leukemia Steering Committee

- 2016-present: Leukemia and Lymphoma Society of America. Career Development Awards Study Section.
- 2015-present: Ad Hoc member NCI R21 study section
- 2015-present: Samuel Waxman Cancer Research Foundation Board of Directors
- 2015-present: External Advisory Board, Mount Sinai Myeloproliferative Neoplasm P01 (R. Hoffman, PI), Mount Sinai Hospital School of Medicine
- 2010-present: University of Chicago Cancer Center External Advisory Committee
- 1994-present: Member of ad hoc NCI special study sections for a variety of program project grants and Cancer center core grants
- 2015-17: Member, NCI Leukemia Steering Committee
- 2014: Chair, Study Section, Department of Defense Bone Marrow Failure Research Program
- 2010-15: ASH RTAF Grand Study Section
- 2010, 2012: Grant Reviewer Deutsche Forschungsgemeinschaft

Journal Service:

- 1993-present: Ad-hoc Reviewer, Blood
Ad-hoc Reviewer, Haematologica
Ad-hoc Reviewer, Journal of Clinical Oncology
Ad-hoc Reviewer, Leukemia
Ad-hoc Reviewer, Leukemia Research
Ad-hoc Reviewer, Cancer Research
Ad-hoc Reviewer, Clinical Cancer Research
Ad-hoc Reviewer, Molecular Cancer Therapeutics
Ad-hoc Reviewer, Journal of Experimental Hematology
Ad-hoc Reviewer, American Journal of Hematology
- 1997-14: Member, Editorial Board, and Cancer Information Summaries: Adult Treatment, Physicians Data Query, National Institutes of Health
- 2003-05 Member, Editorial Board, *Journal of Clinical Oncology*

Professional Service for Professional Organizations:

American Association for Cancer Research

- 2018-2020 Member, inaugural AACR Hematologic Malignancies Task Force

Society for Immunotherapy of Cancer

- 2014-present Acute Leukemia CIG Subcommittee, Society for Immunotherapy of Cancer

Cantex Pharmaceuticals

- 2016-present Chair, Data Safety and Monitoring Board, Cantex Pharmaceuticals

National Institutes of Health/National Heart, Lung, and Blood Institute

- 2015-present Co-Chair, NHLBI/NCS National MDS Natural History Study

University of Chicago Comprehensive Cancer Center

- Present Member, External Advisory Committee

Karyopharm Corporation

- 2015 Scientific Advisory Board, Karyopharm Corporation

Sunesis Pharmaceutical Corporation

2015 Scientific Advisory Board, Sunesis Pharmaceutical Corporation

Chronic Myelomonocytic Leukemia

2015 Scientific Advisory Board, Faster Cures, Chronic Myelomonocytic Leukemia

National Cancer Institute

2015 Special expert NCI Leukemia Steering Committee (LKSC)

2013-17 Member, NCCN Leukemia Guidelines Committee

Kyowa Hakko Kirin Pharma, Inc.

2013-present Data and Safety Monitoring Board (DSMB) Kyowa Hakko Kirin Pharma, Inc.

National Comprehensive Cancer Center Network

2013-17 Member, NCCN Leukemia Guidelines Committee

1998-13 National Comprehensive Cancer Center Network, Member MDS Committee

Celgene Corporation

2011-14 Data and Safety Monitoring Board (DSMB) Celgene Corporation

2010-present Global Scientific Advisory Board in Myelodysplastic Syndrome, Celgene Corporation

American Society of Hematology

2005-07 Chair, ASH MDS Abstract Reviews

2004-05 ASH Abstract Reviewer

Eastern Cooperative Oncology Group

2004-present Eastern Cooperative Oncology Group, Member Leukemia Correlative Science Committee

1996-present Eastern Cooperative Oncology Group, Member Leukemia Core Committee

Meeting Planning/Participation

2017 Chairing Organizer, Cancer Genetics Workshops, Jekyll Island, GA

2015 Chair, 13th Biannual International Myelodysplastic Syndrome Symposium (MDS 2015), Washington, DC

2015 Organizer 7th Biennial Workshop on the “Clinical Translation of Epigenetics in Cancer Therapy,” St. Augustine, FL.

2013 Organizer 6th Biennial Workshop on the “Clinical Translation of Epigenetics in Cancer Therapy,” Asheville, NC

2011 Organizer 5th Biennial Workshop on the “Clinical Translation of Epigenetics in Cancer Therapy,” San Diego, CA

2009 Organizer 4th Biennial Workshop on Clinical Targeting of Epigenetic Changes in Cancer Therapeutics, Miami, FL

2007 Organizer 3rd ‘Baltimore’ Workshop on Clinical Targeting of Epigenetic Changes in Cancer Therapeutics, Phoenix, AZ

2006-13 Chair, Hematologic Malignancies Committee, Mayo Phase 2 Consortium

2006 New Frontiers in the Treatment of Myelodysplasia, Baltimore, MD

2005 Organized 2nd ‘Baltimore’ Workshop on Clinical Targeting of Epigenetic Changes in

2003 Cancer Therapeutics, Charleston, SC
Co-organizer of SKCCC/NCI-CTEP-sponsored Workshop on Therapies Targeting Gene Re-expression in Cancer, Baltimore, MD.

Yale University Service:

Departmental Committees

2018-present Co-chair, Clinical Research Oversight Committee
2018-present Co-chair, CAR-T Treatment Protocol Subcommittee
2018-present Member, CAR-T Steering Committee
2016-present Member, Cancer Center Protocol Life Cycle Committee
2015-present Member, Cancer Center Clinical Research Oversight Committee
2014-present Co-Host, Yale Cancer Answers Radio Program
2013-present Member, Cancer Committee
2013-present Member, Cancer Center QPSQC
2013-present Member, HIC1
2013-present Member, Cancer Center Protocol Review Committee
2013-15 Member, Cancer Center Outpatient Care Committee
2013-15 Cancer Center Retreat Planning Committee

Yale-New Haven Hospital Boards & Committees

2013-present YNHH MD/PSM Committee

Bibliography

Peer-Reviewed Original Research

1. Behrman, H.R., Hall, A.K., Preston, S.L., **Gore, S.D.** Antagonistic interactions of adenosine and prostaglandin F₂ alpha modulate acute responses of luteal cells to luteinizing hormone. *Endocrinology* 1983; 110:38-46.
2. Brennan, T., Ohkawa, R., **Gore, S.D.**, and Behrman, H.R. Adenine-derived purines increase ATP levels in the luteal cell: Evidence that cellular ATP levels limit cAMP production by LH. *Endocrinology* 1983; 112:499.
3. Behrman, H.R., Hall, A.K., **Gore, S.D.**, Dorflinger, L.J., Luborsky, J.L., and Polan, M.L. Paracrine regulation of the corpus luteum by purines, prostaglandins, and peptides. *Prog Clin Biol Res* 1983; 112:221-238.
4. Behrman, H.R., Hall, A.K., **Gore, S.D.**, Dorflinger, L.J., Luborsky, J.L., and Polan, M.L. Paracrine regulation of the corpus luteum by purines, prostaglandins, and peptides. *Prog Clin Biol Res* 1983; 112:221-238.
5. Behrman, H.R., Polan, M.L., Ohkawa, R., Laufer, N., Luborsky, J.L., Williams, A.T., and **Gore, S.D.** Purine modulation of LH action in gonadal cells. *J Steroid Biochem* 1983; 19:789-793.
6. Dorflinger, L.J., Luborsky, J.L., **Gore, S.D.**, and Behrman, H.R. Inhibitory characteristics of prostaglandin F₂ alpha in the rat luteal cell. *Mol Cell Endocrinol* 1983; 33: 225-241.
7. **Gore, S.D.**, Behrman, H.R. Alteration of transmembrane sodium and potassium gradients inhibits the action of LH in the luteal cell. *Endocrinology* 1984; 114: 2020-2031.
8. **Gore, S.D.**, Kastan, M.B., Goodman, S.N., and Civin, C.I. Detection of minimal residual T cell acute lymphoblastic leukemia by flow cytometry. *J of Immunol Methods* 1990; 132:275-286.
9. **Gore, S.D.**, Kastan, M.B., and Civin, C.I. Normal human bone marrow terminal

- deoxynucleotidyl transferase (TdT) positive cells include T cell precursors and possible lymphoid stem cells. *Blood* 1991; 77(8):1681-1690.
10. Larson, R.A., Lukin, C.L., Daly, K.M., Mick, R., **Gore, S.D.**, and LeBeau, M.M. Circulating immune complexes correlate with remission duration in acute myeloid leukemia. *Leukemia* 1991; 5(2):131-173.
 11. Hurwitz, C.A., **Gore, S.D.**, Stone, K.D., Civin, C.I., Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute lymphoblastic leukemia cells. *Leukemia* 1992; 6(4):233-239.
 12. **Gore, S.D.**, Weng, L.J., Burke, P.J. Validation of Flow Cytometric Determination of Ki67 Expression as a Measure of Growth Factor Response in Acute Myelogenous Leukemia. *Experimental Hematology* 1993; 21(13):1702-1708.
 13. **Gore, S.D.**, Donnenberg, A.D., Zehnbauser, B.A., Weng, L.J., Burke, P.J., Granulocyte-macrophage colony-stimulating factor (GM-CSF), given concurrently with induction therapy for acute myelogenous leukemia (AML), augments the syndrome of T-lymphocyte recovery. *Leukemia* 1994; 8:409-419.
 14. Rowinsky E.K., Adjei, A.A., Donehower, R.C., **Gore, S.D.**, Jones, R.J., Burke, P.J., Cheng, Y-C, Grochow, L.B., and Kaufmann, S.H. A phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. *Journal Clinical Oncology* 1994; 12(10):2193-2203.
 15. **Gore, S.D.**, Weng, L.J. and Burke, P.J. Identification of growth factor-responsive acute myelogenous leukemia based on factor-dependence for survival and proliferation. *Leukemia* 1994; 8:1854-1863.
 16. **Gore, S.D.**, Weng, L-J, Jones, R.J., Cowan, K., Zilcha, M., Piantadosi, S., and Burke, P.J. Impact of in vivo administration of Interleukin-3 on proliferation, differentiation and chemosensitivity of acute myeloid leukemia. *Clinical Cancer Research* 1995; 1:295-303.
 17. **Gore, S.D.**, Amin, S., Weng, L.I., and Civin, C.I. Steel factor supports proliferation of isolated human CD34+ cells in the absence of other growth factors. *Experimental Hematology* 1995; 23:413-421.
 18. Kaufmann, S.H., Karp, J.E., Burke, P.J., and **Gore, S.D.** Addition of etoposide to initial therapy of adult acute lymphoblastic leukemia: A combined clinical and laboratory study. *Leukemia and Lymphoma* 1996; 23:71-83.
 19. Rowinsky, E.K., Kaufmann, S.H., Baker, S.D., Miller, C., Sartorius, S.E., Bowling M.K., Chen, T-L, Donehower, R.C. and **Gore, S.D.** A phase I and pharmacologic study of topotecan on a 30- minute infusion daily for five-day schedule in patients with refractory acute leukemia. *Clinical Cancer Research* 1996; 2:1921-1930.
 20. Horn, T.D., Lehmkuhle, M.A., **Gore, S.D.**, Hood, A., Burke P.J. Histopathologic spectrum of the eruption of lymphocyte recovery. *Journal of Cutaneous Pathology* 1996; 23:242-246.
 21. Horn T, Lehmkuhle MA, **Gore, S.**, Hood A, Burke P. Systemic cytokine administration alters the histology of the eruption of lymphocyte recovery. *J Cutan Pathol* 1996; 23(3):242-6.
 22. Kaufmann, S.H., **Gore, S.D.**, Letendre, L., Svingen, P.A., Kottke, T., Buckwalter, C.A., Jones, R.J., Grochow, L.B., Burke, P.J., Donehower, R.C., and Rowinsky, E.K. Factors affecting topotecan sensitivity in human leukemia samples. *Annals of N.Y. Academy of Science* 1996; 803:128-142.
 23. Kaufmann, S.H., Svingen, P.A., **Gore, S.D.**, Armstrong, D.A., Cheng, Y-C, and Rowinsky, E.K. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. *Blood* 1997; 89:2098-2104.
 24. **Gore, S.D.**, Samid, D., Weng, L-J. Impact of the putative differentiating agent's sodium

- phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. *Clinical Cancer Research* 1997; 3(10):1755-1762.
25. Kaufmann, S.H., Karp, J.E., Svingen, P.A., Krajewski, S., Burke, P.J., **Gore, S.D.**, and Reed, J.C. Elevated expression of MCL-1 at the time of leukemic relapse. *Blood* 1998; 91(3):991-1000.
 26. Kaufmann, S.H., **Gore, S.D.**, Jones, R.J., Miller, C.B., Zwelling, L.A., Schneider, E., Burke, P.J., and Karp, J.E. Topoisomerase II and the response to anti-leukemic therapy. *Leukemia and Lymphoma* 1998; 29(3-4):217-237.
 27. Smith, B.D., Bambach, B.J., Vala, M.S., Barber, J.P., Enger, C., Brodsky, R.A., Burke, P.J., **Gore, S.D.**, and Jones, R.J. Inhibited apoptosis and drug resistance in acute myeloid leukemia. *British Journal of Hematology* 1998; 102:1042-1049.
 28. **Gore, S.D.**, Rowinsky, E.K., Miller, C.B., Griffin, C., Chen, T-L, Borowitz, M., Donehower, R.C., Burks, K.L., Armstrong, D.K., Burke, P.J., Grever, M.R., and Kaufmann, S.H. A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia, *Clinical Cancer Research* 1998; 4(11):2677-2689.
 29. **Gore, S.D.**, Burke, P.J., and Weng, L.J. Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia. *Leukemia and Lymphoma* 1998; 29(3-4):339-350.
 30. DiGiuseppe, J.A., Kastan, M.B., Weng, L-J, and **Gore, S.D.** Cytoprotective effects of hematopoietic growth factors on primary human acute myeloid leukemia's are not mediated through changes in BCL-2, BAX, or p21^{WAF1/CIP1}. *In Vivo* 1999; 13(1):1-6.
 31. DiGiuseppe, J.A., Weng, L-J, Yu, K.H., Shen, F., Kastan, M.B., Samid, D., and **Gore, S.D.** Phenylbutyrate-Induced G1 arrest and apoptosis in myeloid leukemia cells: Structure-function analysis. *Leukemia* 1999; 13:1243-1253.
 32. Yu, K.H., Weng, L-J, Fu, S, and **Gore, S.D.** Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all trans-retinoic acid. *Leukemia* 1999; 13:1258-1265.
 33. Flinn, I.W., Goodman, S.N., Post, L., Jamison, J., Miller, C.B., **Gore, S.D.**, Diehl, L., Willis, C., Ambinder, R.F., Byrd, J.C. A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL. *Ann Oncol.* 2000 un; 11(6):691-5.
 34. Svingen, P.A., Karp, J.E., Krajewski, S., Mesner, P.W. Jr., **Gore, S.D.**, Burke, P.J., Reed, J.C., Lazebnik, Y.A., Kaufmann, S.H. Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. *Blood* 2000 Dec 1; 96(12):3922-31.
 35. Cheson, B.D., Bennett, J.M. Bennett, Kantarjian, H., Pinto, A., Schiffer, C.A., Nimer, S.D., Lowenberg, B., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Wijermans, P.W., **Gore, S.D.**, and Greenberg, P.L. Report of an international working group to standardize response criteria for myelodysplastic syndromes. *Blood* 2000; 96: 3671-3674.
 36. Sotomayor, E.M., Pinatadosi, S., Miller, C. B., Karp, J.E., Jones, R.J., Rowley, S. D., Kaufmann, S.H., Braine, H., Burke, P.J., and **Gore, S.D.** Long term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: Impact of induction Ara-C dose and post-remission therapy. *Leukemia Research* 2001; 26:461-471.
 37. **Gore, S.D.**, Weng, L., Zhai, S., Figg, W.D., Donehower, R.D., Dover, G.J., Grever, M., Griffin, C.A., Grochow, L.B., Rowinsky, E. K., Zabalena, Y., Hawkins, A.L., Burks, K., and Miller, C.B. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. *Clinical Cancer Research* 2001;

- 7:2330-2339.
38. Lumkul, R., Goring, N.C., Malehorn, M.T., Hoehn, G.T., Zheng, R., Baldwin, B., Small, D., **Gore, S.D.**, Smith, B.D., Meltzer, P., Civin, C.I. Human AML Cells in NOD/SCID Mice: Engraftment Potential and Gene Expression. *Leukemia* 2002; 16:1818-1826.
 39. **Gore, S.D.**, Weng, L., Zhai, S., Figg, W.D., Donehower, R.D., Dover, G.J., Grever, M., Griffin, C.A., Grochow, L.B., Rowinsky, E. K., Zabalena, Y., Hawkins, A.L., Burks, K., and Miller, C.B. Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Clinical Cancer Research* 2002; 8:963-970.
 40. Saif, M.W., Hopkins, J.L., **Gore, S.D.** Autoimmune Phenomena in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. *Leukemia and Lymphoma* 2002; 43(11): 2083 - 2092.
 41. Smith, B.D., Jones, R.J., Lee, S.M., Piantadosi, S., Vala, M.S., Fuller, D., **Gore, S.D.**, Noga, S.J., O'Donnell, P.V., Braine, H., Vogelsang, G.B., Fuchs, E.J., Flinn, I.W., Brodsky, R.A., Ambinder, R.F., Miller, C.B., Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukemia beyond first remission: a 10-year experience. *Br J Haematol* 2002. 117:907-913.
 42. Meng XW, Chandra J, Loegering D, Van Becelaere K, Kottke TJ, **Gore, S.D.**, Karp JE, Sebolt-Leopold J, Kaufmann SH. Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. *J Biol Chem* 2003; 278(47):47326-39.
 43. Orlowski, Robert Z., Mills, Sharon R., Hartley, Eric E., Ye, Xiaobu, Piantadosi, Steven, Ambinder, Richard F., **Gore, S.D.**, and Miller, Carole B. Oral Valacyclovir as Prophylaxis against Herpes Simplex Virus Reactivation during High Dose Chemotherapy for Leukemia. *Leukemia & Lymphoma* 2004; 45(11): 2215-9.
 44. Zhao, Ming, Rudek, Michelle A., He, Ping, Carol Hartke, Carol, **Gore, S. D.**, Michael Carducci, Baker, Sharyn D. Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high performance liquid chromatograph. *Journal of Chromatography B* 2004; 813(1-2):81-8.
 45. **Gore S.D.**, Smith B.D., Gojo, I., Grever, M., Kaufmann, S.H., Letendre, L., Leonard, D.G., Marcucci, G., Miller, C.B., Morris, L., Piantadosi, S., Prior, T., Stock, W., Karp, J.E. Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia. *Am J Hematol* 2005; 79(2):119-27.
 46. Rudek, M.A., Zhao, M., He, P., Hartke, C., Gilbert, J., **Gore, S.D.**, Carducci, M.A., Baker, S.D. Pharmacokinetics of 5- azacytidine given with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. *J Clin Oncol* 2005; 23(17):3906-11.
 47. Karp, J.E., Passaniti, A., Gojo, I., Kaufmann, S., Biblem K., Garimella, T.S., Greer, J., Briel, J., Smith, B.D., **Gore, S.D.**, Tidwell, M.L., Ross, D.D., Wright, J.J., Colevas, A.D., Bauer, K.S. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. *Clin Cancer Res* 2005; 11(23):8403-12.
 48. Varghese, S., Gupta, D., Baran, T., Jiemjit, A., **Gore, S.D.**, Casero, R.A., Jr., Woster, P.M. Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors. *J Med Chem* 2005; 48(20):6350-65.
 49. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Bowenber, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., deWitte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., **Gore, S.D.**, Schiffer, C.A. and Kantarjian, H. Clinical Application and Proposal for Modification of the International Working Group (IWG) Response Criteria in

- Myelodysplasia. *Blood* 2006; 108: 419-425.
50. **Gore, S.D.**, Baylin, S., Sugar, E., Carraway, H., Miller, C.B., Carducci, M., Grever, M., Galm, O., Dausies, T., Karp, J.E., Rudek, M.A., Zhao, M., Smith, B.D., Manning, J., Jiemjit, A., Dover, G., Mays, A., Zwiebel, J., Murgo, A., Weng, L.J., Herman, J.G. Combined DNA Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid Neoplasms. *Cancer Research* 2006; 66(12):6361-6369.
 51. Gojo, I., Jiemjit, A., Trepel, J.B., Sparreboom, A., Figg, W.D., Rollins, S., Tidwell, M.L., Greer, J., Chung, E.J., Lee, M.J., **Gore, S.D.**, Sausville, E.A., Zwiebel, J., Karp, J.E. Phase 1 and pharmacological study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias, *Blood* 2006 (e-pub ahead of print).
 52. Fandy, T.E., Ross, D.D., **Gore, S.D.**, Srivastava, R.K. Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIP (L). *Cancer Chemother Pharmacol* 2007 Aug;60(3):313-9. Epub 2006 Dec 23. PMID: 17187253
 53. Karp, J.E., Smith, B.D., Levis, M.J., **Gore, S.D.**, Greer, J., Hattenberg, C., Briel, J., Jones, R.J., Wright, J.J., Colevas, A.D. Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor Risk Acute Myelogenous Leukemia. *Clin Can Res* 13(15) 4468-4473, 2007.
 54. Karp, J.E., Riclis, R.M., Balakrishnan, K., Briel, J., Greer, J., **Gore, S.D.**, Smith, B.D., McDevitt, M.A., Carraway, H., Levis, M.J., Gandhi, V. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. *Blood* 2007 Sept 15; 11(6):1762-9.
 55. Min-Jung Lee, Eun Joo Chung, Sunmin Lee, Joon-Yong Chung, William G. Telford, Edward A. Sausville, Ican Gojo, Judith E. Karp, **Steven D. Gore** Veena Kapoor, Yeong Sang Kim, Shivaani Kummur, Martin Gutierrez, Stephen M. Hewitt, and Jane B. Trepel. A Cell Microarray Platform for Anti-Cancer Drug Development. *Drug Development Research* 2007 August; 58(5):226-234.
 56. Karp, J.E., Smith, B.D., Gojo, I., Lancet, J.E., Greer, J., Klein, M., Morris, L., Levis, M.J., **Gore, S.D.**, Wright, J.J., Garrett-Mayer, E. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. *Clin Cancer Res* 2008, May15; 14(10)3077-82.
 57. Jiemjit, A., Fandy, T.E., Carraway, H., Bailey, K.A., Baylin, S., Herman, J.G., **Gore, S.D.** p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. *Oncogene* 2008, Jun 5; 27(25):3615-23. PMID: 18223691
 58. Zelent, A., Petrie, K., Boix-Chornet, M., Melnick, A.M., Waxman, S., **Gore, S.D.** Depression in the desert: the third workshop on clinical translation of epigenetics in cancer therapeutics. *Cancer Res* 2008, July 1;68(13):4967-70. PMID: 18593891
 59. **Gore, S.D.** New agents for the treatment of AML recent study findings. *Clin Adv Hematol Oncol* 2008, Nov; 6(11):6-8. PMID: 19205109
 60. **Gore, S.D.**, Hermes-DeSantis, E.R. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. *Cancer Control* 2008 Oct; 15 Suppl: 40-9.
 61. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., **Gore, S.D.**, Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C., Silverman, L.R. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. *Lancet Oncol* 2009 March; 10(3):223-32. PMID: 19230772
 62. Karp, J.E., Flatten, K., Feldman, E.J., Greer, J.M., Loegering, D.A., Rivklis, R.M., Morris, L.E., Ritchie, E., Smith, B.D., Ironside, V., Talbott, T., Roboz, G., Le, S.B.,

- Meng, X.W., Schneider, P.A., Dai, N.T., Adjei, A.A., **Gore, S.D.**, Levis, M.J., Wright, J.J., Garrett-Mayer, E., Kaufmann, S.H. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: A preclinical and phase I trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. *Blood* 2009 May 14; 113(20):4841-52. PMID: PMC2686135
63. Oliansky, D.M., Antin, J.H., Bennett, J.M., Deeg, H.J., Engelhardt, C., Heptinstall, K.V., de Lima, M., **Gore, S.D.**, Potts, R.G., Silverman, L.R., Jones, R.B., McCarthy, P.L., Jr., Hahn, T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. *Biol Blood Marrow Transplant* 2009 May; 15(5):650. PMID: 19167676
64. Griffiths, E.A., **Gore, S.D.** MicroRNA: miR-ly regulators of DNMMT? *Blood* 2009 Jun 18; 113(25):6269-70. No abstract available. PMID: 19541832
65. Fandy, T.E., Herman, J.G., Kerns, P., Jiemjit, A., Sugar, E.A., Choi, S.H., Yang, A.S., Aucott, T., Dausers, T., Odchimar-Reissig, R., Licht, J., McConnell, M.J., Nasrallah, C., Kim, M.K., Zhang, W., Sun, Y., Murgo, A., Espinoza-Delgado, I., Oteiza, K., Owoeye, I., Silverman, L.R., **Gore, S.D.**, Carraway, H.E. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. *Blood* 2009 Sep 24; 114(13):2764-73. PMID: PMC2756131
66. Lin, J., Gilbert, J., Rudek, M.A., Zwiebel, J.A., **Gore, S.D.**, Jiemjit, A., Zhao, M., Baker, S.D., Ambinder, R.F., Herman, J.G., Donehower, R.C., Carducci, M.A. A Phase I Dose Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors. *Clin Cancer Res* 2009 October 1; 15(19):6241-6249. PMID: PMC2845396.
67. Litzow, M.R., Othus, M., Cripe, L.D., **Gore, S.D.**, Lazarus, H.M., Lee, S.J., Bennett, J.M., Paietta, E.M., Dewald, G.W., Rowe, J.M., Tallman, M.S.; for the Eastern Cooperative Oncology Group Leukemia Committee. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. *Br J Haematol* 2009 Oct 5. PMID: PMC2809127
68. Schaefer, E.W., Loaiza-Bonilla, A., Juckett, M., DiPersio, J.F., Roy, V., Slack, J., Wu, W., Laumann, K., Espinoza-Delgado, I., **Gore, S.D.** Mayo P2C Phase II Consortium. A phase 2 study of vorinostat in acute myeloid leukemia. *Haematologica* 2009 Oct; 94(10):1375-82. PMID: PMC2754953
69. Figueroa, M.E., Skrabanek, L., Li, Y., Jiemjit, A., Fandy, T.E., Paietta, E., Fernandez, H., Tallman, M.S., Grealley, J.M., Carraway, H., Licht, J.D., **Gore, S.D.**, Melnick, A. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. *Blood* 2009 Oct 15; 114(16):3448-58. PMID: PMC2765680
70. Ye, Y., McDevitt, M.A., Guo, M., Zhang, W., Galm, O., **Gore, S.D.**, Karp, J.E., Maciejewski, J.P., Kowalski, J., Tsai, H.L., Gondek, L.P., Tsai, H.C., Wang, X., Hooker, C., Smith, B.D., Carraway, H.E., Herman, J.G. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. *Cancer Res* 2009 Nov 1; 69(21):8482-90. PMID: PMC3087599
71. Karp, J.E., Blackford, A., Smith, B.D., Alino, K., Seung, A.H., Bolaños-Meade, J., Greer, J.M., Carraway, H.E., **Gore, S.D.**, Jones, R.J., Levis, M.J., McDevitt, M.A., Doyle, L.A., Wright, J.J. Clinical activity of sequential flavopiridol, cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. *Leuk Res* 2009 Dec 3. PMID: PMC28755369
72. Fenaux, P., Mufti, G., Hellstrom-Lindberg, E., Santini, Valeria, S., Gattermann, N.,

- Germing, U., Santz, G., List, A., **Gore, S.D.**, Seymour, J., Dombret, H., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C.L., Silverman, L. Azacitidine Prolongs Overall Survival Compared with Conventional Care Regimens in Older Adult Patients with Low Bone Marrow Blast Count (20-30% Acute Myeloid Leukemia. *J. Clinical Oncology* 2010 Feb 1;28(4):562-9. PMID: 20026804
73. **Gore, S.D.**, Gojo, I., Sekeres, M.A., Morris, L., Devetten, M., Jamieson, K., Redner, R.L., Arceci, R.J., Owoeye, I., Dausers, T., Schachter, E., Gallagher, R. A Single Cycle of Arsenic Trioxide-based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia. *Journal of Clin Oncology* 2010 Feb 20;28(6):1047-53. PMCID: PMC2834430
74. Fenaux, P., Gattermann, N., Syemour, J.F., Hellstrom-Lindberg, E., Mufti, G.J., Duehrsen, U., **Gore, S.D.**, Ramos, F., Beyne-Rauzy, O., List, A., McKenzie, D., Backstrom, J., Beach, C.L. Prolonged Survival with Improved Tolerability in Higher-Risk Myelodysplastic Syndromes: Azacitidine compared with Low Dose Ara-C. *British Journal of Haematology* 2010 Apr; 149(2):244-9. PMID: 20136825
75. Karp, J., Blackford, A., Smith, B.D., Alino, K., Seung, Hatfield, A., Bolanos-Meade, J., Greer, J., Carraway, H.E., **Gore, S.D.**, Jone, R.J., Levis, M.J., McDevitt, M.A., Doyle, L.A., Wright, J.J. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. *Leukemia Res* 2010 Jul; 34(7):877-82. PMCID: PMC2875369
76. Santini, V., Fenauz, P., Mufti, G.J., Hellstrom-Lindberg, E., Silverman, L.R., List, A., **Gore, S.D.**, Syemour, J.F., Backstrom, J., Beach, C.L. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. *European Journal of Haematology* 2010 Aug; 85(2):130-8. PMID: 20394651
77. Pratz, K.W., Cho, E., Levis, M.J., Karp, J.E., **Gore, S.D.**, McDevitt, M., Stine, A., Zhao, M., Baker, S.D., Carducci, M.A., Wright, J.J., Rudelk, M.A., Smith, B.D. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. *Leukemia* 2010 Aug; 24(8):1437-44. PMCID: PMC2921005
78. Griffiths, E.A., **Gore, S.D.**, Hooker, C., McDevitt, M.A., Karp, J.E., Smith, B.D., Mohammad, H.P., Ye, Y., Herman, J.G., Carraway, H.E. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. *Leuk Lymphoma* 2010 Sep;51(9):1711-9. PMID: 20795789
79. Griffiths, E.A., **Gore, S.D.**, Hooker, C.M., Mohammad, H.P., McDevitt, M.A., Smith, B.D., Karp, J.E., Herman, J.G., Carraway, H.E. Epigenetic differences in cytogenetically normal versus an abnormal acute myeloid leukemia. *Epigenetics* 2010 Oct 1;5(7):590-600. PMCID: PMC3052845
80. Seymour, J.F., Fenauz, P., Silverman, L.R., Ghulam, M.J., Hellstrom-Lindberg, E., Santini, V., List, A.F., **Gore, S.D.**, Backstrom, J., McKenzie, D., Beach, C.L. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. *Crit Rev Oncol Hematol* 2010 Dec;76(3):218-27 PMID: 20451404
81. Greenberg, P.L., Attar, E., Bennett, J.M., Bloomfield, C.D., De Castro, C.M., Deeg, H.J., Foran, J.M., Gaensler, K., Garcia-Manero, G., **Gore, S.D.**, Head, D., Komrokji, R., Maness, L.J., Millenson, M., Nimer, S.D., O'Donnell, M.R., Schroeder, M.A., Shami, P.J., Stone, R.M., Thompson, J.E., Westervelt, P. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. *J Natl Compr Canc Netw* 2011 Jan;9(1):30-56. PMID: 21233243
82. Smith, B.D., Jones, R.J., Cho, E., Kowalski, J., Karp, J.E., **Gore, S.D.**, Vala, M., Meade,

- B., Baker, S.D., Zhao, M., Piantoadosi, S., Zhang, Z., Blumenthal, G., Warlick, E.D., Brodsky, R.A., Murgo, A., Rudek, M.A., Matsui, W.H. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatins 1 and GM-CSF. *Luek Res* 2011 Jan; 35(1):87-94. PMID: PMC3033102
83. Kasamon, Y.L., Jones, R.J., Gocke, C.D., Blackford, A.L., Seifter, E.J., Davis-Sproul, J.M., **Gore, S.D.**, Ambinder, R.F. Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas. *Biol Blood Marrow Transplant* 2011 Mar; 17(3):365-73. PMID: PMC2980559
84. Karp, J.E., Smith, B.D., Resar, L.S., Greer, J.M., Blackford, A., Zhao, M., Moton-Nelson, D., Alino, K., Levis, M.J., **Gore, S.D.**, Joseph, B., Carraway, H., McDevitt, M.A., Bagain, L., Mackey, K., Briel, J., Doyle, L.A., Wright, J.J., Rudek, M.A. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. *Blood* 2011 Mar 24; 117(12):3302-10. PMID: PMC3069672
85. Bolanos-Meade, J., Smith, B.D., **Gore, S.D.**, McDevitt, M.A., Luznik, L., Fuchs, E.J., Jones, R.J. 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. *Biol Blood Marrow Transplant* 2011 May; 17(5):754-9 PMID: PMC3090635
86. Garcia-Manero, G., **Gore, S.D.**, Cogle, C., Ward, R., Shi, T., Macbeth, K.J., Laille, E., Giordano, H., Sakoian, S., Jabbour, E., Kantarjian, H., Skikne, B. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. *J Clin Oncol* 2011 June 20; 29(18):2521-7 PMID: 21576646
87. Silverman, L.R., Fenauz, P., Mufti, G.J., Santini, V., Hellstrom-Lindberg, E., Gattermann, N., Sanz, G., List, A.F., **Gore, S.D.**, Seymour. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. *Cancer* 2011 June 15; 117(12):2697-702. PMID: 21656747
88. Zhou, L., Opalinska, J., Sohal, D., Yu, Y., Mo, Y., Bhagat, T., Abdel-Wahab, O., Fazzari, M., Figueroa, M., Alencar, C., Zhang, J., Kambhampati, S., Parmar, S., Nischal, S., Hueck, C., Suzuki, M., Freidman, E., Pellagatti, A., Boutwood, J., Steidl, U., Sautharajah, Y., Yajnik, V., McMahan, C., **Gore, S.D.**, Plataniias, L.C., Levine, R., Melnick, A., Wickrema, A., Grealley, J.M., Verma, A. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and eveal Dock4 as a candidate pathogenic gene on chromosome 7q. *J Biol Chem* 2011 Jul 15; 286(28):25211-23. PMID: PMC3137092
89. Prebet, T., **Gore, S.D.**, Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Dreyfus, F., Rauzy, O.B., Recher, C., Ades, L., Quesnel, B., Beach, C.L., Fenauz, P., Vey, N. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. *J Clin Oncol* 2011 Aug 20; 29(24):3322-7. PMID: 21788559
90. DeZern, A.E., Sung, A., Kim, S., Smith, B.D., Karp, J.E., **Gore, S.D.**, Jones, R.J., Fuchs, E., Luznik, L., McDevitt, M., Levis, M. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. *Biol Blood Marrow Transplant* 2011 Sep; 17(9):1404-9 PMID: PMC3110512
91. Karp, J.E., Vener, Ti, Raponi, M., Ritchie, E.K., Smith, B.D., **Gore, S.D.**, Morris, L.E., Feldman, E.J., Greer, J.M., Malek, S., Carraway, H.E., Ironside, V., Galkin, S., Levis, M.J., McDevitt, M.A., Roboz, G.R., Cocco, C.D., Derecho, C., Palma, J., Wang, Y., Kaufmann, S.H., Wright, J.J., Garrett-Mayer, E. Multi-institutional Phase II clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly

92. diagnosed acute myelogenous leukemia. *Blood* 2011 Oct 14. PM. PMID: 22001391
Smith, S.W., Sato, M., **Gore, S.D.**, Baer, M.R., Ke, X., McNally, D., and Davidoff, A. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. *Haematologica* 2012 Jan; 97(1):15-20. Epub 2011 Nov 18. PMID:22102702
93. Davidoff, A.J., Weiss, Smith, S., Baer, M.R., Ke, X., Bierenbaum, J.M., Hendrick, F., McNally, D.L., **Gore, S.D.** Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes. *Haematologica* 2012 Jan;97(1):128-32. PMID:22210329
94. Karp, J.E., Garrett-Mayer, E.L., Estey, E.H., Rudek, M.A., Smith, B.D., Greer, J.M., Drye, D.M., Mackey, K., Dorcy, K.S., **Gore, S.D.**, Levis, M.J., McDevitt, M.A., Carraway, H.E., Pratz, K.W., Gladstone, D.E., Showell, M.M., Othus, M., Doyle, L.A., Wright, J.J., Pagel, J.M. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. *Haematologica* 2012 Jun 24. [Epub ahead of print].
95. Prebet, T., Thepot, S., **Gore, S.D.**, Dreyfus, F., Fenaux, P., Vey, N. Outcome of patients with low risk myelodysplasia after azacitidine treatment failure. *Haematologica* 2013 Feb; 98(2): e18-9. PMID: 22983576
96. Karp, J.E., Thomas, B.M., Greer, J.M., Sorge, C., **Gore, S.D.**, Pratz, K.W., Smith, B.D., Flatten, K.S., Peterson, K., Schneider, P., Mackey, K., Freshwater, T., Levis, M.J., McDevitt, M.A., Carraway, H.E., Gladstone, D.E., Showel, M.M., Loechner, S., Parry, D.A., Horowitz, J.A., Isaacs, R., Kaufmann. Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias. *Clin Cancer Res* 2012 Dec 15; 18(24): 6723-31. PMCID: PMC3596113
97. Zandberg, D.P., Huang, T.Y., Ke, X., Baer, M.R., **Gore, S.D.**, Weiss, Smith, S., Davidoff, A.J. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults. *Haematologica* 2013 Apr;98(4):584-90 PMID:23144192
98. **Gore, S.D.**, Fenaux, P., Santini, V., Bennett, J.M., Silverman, L.R., Seymour, J.F., Hellstrom-Lindberg, E., Swern, A.S., Beach, C.L., List, A.F. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. *Haematologica* 2013 Jul; 98(7):1067-72. PMID: 23585522
99. Davidoff, A.J., Weiss, S.R., Baer, M.R., Ke, X., Hendrick, F., Zeidan, A., **Gore, S.D.** Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines. *Leuk Res* 2013 Jun; 37(6):675-80. 2013 Mar 21 PMID: 23523473
100. Zeidan, A.M., **Gore, S.D.**, McNally, D.L., Baer, M.R., Hendrick, F., Mahmoud, D., Davidoff, A.J. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. *Cancer* 2013 Nov 1; 119(21):3870-8. PMID: 23922173
101. Coutre, S.E., Othus, M., Powell, B., Willman, C.L., Stock, W., Paietta, E., Levitan, D., Wetzler, M., Attar, E.C., Altman, J.K., **Gore, S.D.**, Maher, T., Kopecky, K.J., Tallman, M.S., Larson, R.A., Appelbaum, F.R. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. *Br J Haematol.* 2014 May;165(4):497-503 PMID: 24528179

102. Fandy, T.E., Jiemjit, A., Thaker, M., Rhoden, P., Suarez, L., **Gore, S.D.** Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes. *Clin Cancer Res* 2014 Mar 1;20(5):1249-58. PMID: 24423613
103. Zeidner, J.F., Karp, J.E., Blackford, A.L., Smith, B.D., Gojo, I., **Gore, S.D.**, Levis, M.J., Carraway, H.E., Greer, J.M., Ivy, S.P., Pratz, K.W., McDevitt, M.A. A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. *Haematologica* 2014 Apr; 99(4):672-8. PMID: 24362550
104. Seymour, J.F., Bennett, J.M., List, A.F., Mufti, G.J., **Gore, S.D.**, Fenaux, P., Santini, V., Hetzer, J., Songer, S., Skikne, B.S., Beach, C.L. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. *Br J Haematol* Apr; 165(1):49-56. PMID: 24467613
105. Zeidan AM, Lee JW, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabilove J, Erba HP, Katterling RP, Tallman MS, **Gore SD**. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. *Br J Haematol.* 2014 Oct;167(1):62-8. doi: 1111/bjh.13008. Epub 2014 Jul 4. P PubMed PMID: 24995683.
106. Zeidan AM, Lee JW, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabilove J, Erba HP, Tallman MS, **Gore SD**; Eastern Cooperative Oncology Group (ECOG) and North American Leukemia intergroup. Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. *Br J Haematol.* 2014 Aug; 166(3):352-9. doi: 10.1111/bjh.12884. Epub 9. PubMed PMID: 24712482.
107. Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabilove J, ErbaHP, **Gore SD**, Tallman MS. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. *J Clin Oncol.* 2014 Apr 20; 32(12):1242-8. doi: 10.1200/JCO.2013.53.4120. PubMed PMID: 24663049; PubMed Central PMCID: PMC3986386.
108. Zeidner, J.F., Karp, J.E., Blackford, A.L., Smith, B.D., Gojo, I, **Gore, S.D.**, Levis, M.J., Carraway, H.E., Greer, J.M., Ivy, S.P., Pratz, K.W., McDevitt, M.A. A Phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. *Haematologica* 2014 Apr; 99(4):672-8. Doi: 10.3324/haematol.2013.097246. Epub 2013 Dec 20. PMCID: PMC3971077.
109. Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabilove J, Erba HP, **Gore SD**, Tallman MS. *J Clin Oncol.* 2014 Apr 20; 32 (12): 1242-8. PMID: 24663049
110. Hendrick F, Davidoff AJ, Zeidan AM, **Gore SD**, Baer MR. Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes. *Medicare Medicaid Res Rev.* 2014 Nov 26; 4 (4). PMID: 25485173
111. Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, Novak AJ, Feldman AL, Wu X, Ding H, Meng XW, Cerhan JR, Slager SL, Macon WR, Habermann TM, Karp JE, **Gore SD**, Kay NE, Jelinek DF, Witzig TE, Nowakowski GS, Kaufmann SH. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. *Blood.* 2015 Jan 22; 125(4): 658-67. PMID: 25452615
112. Davidoff AJ, Hendrick FB, Zeidan AM, Baer MR, Stuart BC, Shenolikar RA, **Gore SD**. Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part

- D. J Oncol Pract. 2015 Mar;11(2): e190-8. doi: 10.1200/JOP.2014.001527. Epub 2015 Jan 6. PMID: 25563701.
113. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, **Gore SD**, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. *Cancer*. 2015 Mar 15; 121 (6): 876-82. PMID: 25410759
 114. Leech M, Morris L, Stewart M, Smith BD, Bashey A, Holland K, Solomon S, Zhang X, Carraway HE, Pratz K, **Gore SD**, Zeidan AM. Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy. *Clin Lymphoma Myeloma Leuk*. 2015 May; 15(5): 292-7. PMID: 25499624
 115. Duong VH, Baer MR, Hendrick F, Weiss SR, Sato M, Zeidan AM, **Gore SD**, Davidoff AJ. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response. *Leuk Res*. 2015 Jun; 39 (6): 586-91. PMID: 25869077
 116. Lee EJ, Smith BD, Merrey JW, Lee AI, Podoltsev NA, Barbarotta L, Litzow MR, Prebet T, Luger SM, **Gore S**, Streiff MB, Zeidan AM. Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey. *Clin Lymphoma Myeloma Leuk*. 2015 Dec;15(12):766-770. doi: 10.1016/j.clml.2015.07.637. Epub 2015 Aug 6. PMID: 26363982.
 117. Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Ali NA, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, **Gore SD**, Maciejewski JP, List A, Komrokji R. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. *Leukemia*. 2015 Oct 14. doi: 10.1038/leu.2015.283. [Epub ahead of print] PMID:26464171
 118. Garcia-Manero G, **Gore SD**, Kambhampati S, Scott B, Tefferi A, Cogle CR, Edenfield WJ, Hetzer J, Kumar K, Laille E, Shi T, MacBeth KJ, Skikne B. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. *Leukemia*. 2015 Oct 7. doi: 10.1038/leu.2015.265. [Epub ahead of print] PMID: 26442612
 119. Laille E, Shi T, Garcia-Manero G, Cogle CR, Gore SD, Hetzer J, Kumar K, Skikne B, MacBeth KJ. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. *PLoS One*. 2015 Aug 21; 10(8): e0135520. doi: 10.1371/journal.pone.0135520. eCollection 2015. PMID: 26296092
 120. Zeidan AM, Hendrick F, Friedmann E, Baer MR, **Gore SD**, Sasane M, Paley C, Davidoff AJ. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. *J Comp Eff Res*. 2015; 4(4):327-40. doi: 10.2217/ce.15.20. PMID: 26274794
 121. Prebet T, Sun Z, Ketterling RP, Zeidan A, Greenberg P, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Figueroa M, Gabrilove J, Erba HP, Tallman MS, Litzow M, **Gore SD**; Eastern Cooperative Oncology Group and North American Leukemia intergroup. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. *Br J Haematol*. 2016 Feb;172(3):384-91. doi: 10.1111/bjh.13832. Epub 2015 Nov 18. PMID: 26577691.

122. Zeidan AM, Wang R, Davidoff AJ, Ma S, Zhao Y, **Gore SD**, Gross CP, Ma X. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes. *Cancer*. 2016 Mar 11. doi: 10.1002/cncr.29945. [Epub ahead of print] PMID: 26970288.
123. Meyer SE, Qin T, Muench DE, Masuda K, Venkatasubramanian M, Orr E, Suarez L, **Gore SD**, Delwel R, Paietta E, Tallman MS, Fernandez H, Melnick A, Beau MM, Kogan S, Salomonis N, Figueroa ME, Grimes HL. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. *Cancer Discov*. 2016 Mar 25. [Epub ahead of print] PMID: 27016502.
124. Fletcher SA, Cronin AM, Zeidan AM, Odejide OO, **Gore SD**, Davidoff AJ, Steensma DP, Abel GA. Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database. *Cancer*. 2016 Apr 15;122(8):1209-15. doi: 10.1002/cncr.29913. Epub 2016 Feb 23. PMID: 26914833.
125. Zeidan AM, Wang R, Gross CP, **Gore SD**, Huntington SF, Prebet T, Abel GA, Davidoff AJ, Ma X. Modest improvement in survival of patients with excess blasts in the hypomethylating agent era in the United States. *Leuk Lymphoma*. 2016 Aug 25:1-4. [Epub ahead of print] PMID: 27558206
126. Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, **Gore SD**. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. *Br J Haematol*. 2016 Dec;175(5):829-840. doi: 10.1111/bjh.14305. Epub 2016 Sep 21. PMID: 27650975
127. Zeidan AM, Smith BD, Carraway HE, Gojo I, DeZern A, **Gore SD**. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. *Br J Haematol*. 2017 Jan;176(2):241-247. doi: 10.1111/bjh.14407. Epub 2016 Oct 28. PMID: 27790720.
128. Pine AB, Lee EJ, Sekeres M, Steensma DP, Zelterman D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba HP, Garcia-Manero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, Hendrickson JE, **Gore SD**, Zeidan AM. Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. *Transfusion*. 2017 Feb;57(2):289-295. doi: 10.1111/trf.13934. Epub 2016 Nov 22. PMID: 27878822
129. Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, **Gore SD**, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE. A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. *Clin Cancer Res*. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8. PMID: 27503200
130. Prebet T, Toma A, Cluzeau T, Sekeres MA, Vey N, Park S, Al Ali N, Sugrue MM, Komrokji R, Fenaux P, **Gore SD**. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. *Oncotarget*. 2017 Feb 8. doi: 10.18632/oncotarget.15200. [Epub ahead of print] PMID: 28184031
131. Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji J, Karnitz LM, Herman JG, Kinders RJ, Smith BD, **Gore SD**, Carraway HE, Showel MM, Gladstone DE, Levis MJ, Tsai HL, Rosner G, Chen A, Kaufmann SH, Karp JE. A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. *Clin Cancer*

- Res. 2017 Feb 15;23(4):899-907. doi: 10.1158/1078-0432.CCR-16-1274. Epub 2016 Aug 22. PMID: 27551000
132. Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, **Gore SD**, Huntington SF, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study. *Prostate*. 2017 Apr;77(5):437-445. doi: 10.1002/pros.23281. Epub 2016 Nov 21. PMID: 27868212
 133. Zeidan AM, Wang R, Gross CP, **Gore SD**, Huntington SF, Prebet T, Abel GA, Davidoff AJ, Ma X. Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents' era in the United States. *Leuk Lymphoma*. 2017 Apr;58(4):982-985. doi: 10.1080/10428194.2016.1214954. Epub 2016 Aug 25. No abstract available. PMID: 27558206
 134. Sekeres MA, Othus M, List AF, Odenike O, Stone RM, **Gore SD**, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. *J Clin Oncol*. 2017 Aug 20;35(24):2745-2753. doi:10.1200/JCO.2015.66.2510. PubMed PMID: 28486043; PubMed Central PMCID: PMC5562170.
 135. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Hui L, von Keudell G, Wang R, Zeidan AM, **Gore SD**, Ma X, Davidoff AJ, Huntington SF. *Cancer*. 2017 Oct 1;123(19):3763-3771. doi: 10.1002/cncr.30818. Epub 2017 Jun 22. PubMed PMID: 28640385; PubMed Central PMCID: PMC5610636.
 136. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, Platzbecker U, Gotze K, Vey N, Oliva E, Sugrue MM, Bally C, Kelaidi C, Ali NA, Fenaux P, **Gore SD**, Komrokji R. *Oncotarget*. 2017 Jun 14. doi: 10.18632/oncotarget.18477. [Epub ahead of print] PMID: 28645118
 137. Hypomethylating Agents (HMA) Treatment for Myelosplastic Syndromes: Alternatives in the Frontline and Relapse Settings. Uy N, Singh A, **Gore SD**, Prebet T. *Expert Opin Pharmacother*. 2017 Aug;18(12):1213-1224. doi:10.1080/14656566.2017.1349100. Epub 2017 Aug 1. Review. PubMed PMID: 28675065.
 138. Press KR, Uy N, Keefer J, **Gore SD**, Carraway HE, Sakoian S, Prebet T. Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes. *Leuk Lymphoma*. 2018 Mar;59(3):755-757. doi:10.1080/10428194.2017.1354373. Epub 2017 Jul 25. PubMed PMID: 28738707.
 139. Wang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, Huntington SF, Podoltsev NA, Gross CP, **Gore SD**, Ma X. Health Care Use by Older Adults with Acute Myeloid Leukemia at the End of Life. *J Clin Oncol*. 2017 Oct 20;35(30):3417-3424. doi: 10.1200/JCO.2017.72.7149. Epub 2017 Aug 7. PubMed PMID: 28783450; PubMed Central PMCID: PMC5648174.
 140. Norsworthy KJ, DeZern AE, Tsai HL, Hand WA, Varadhan R, **Gore SD**, Gojo I, Pratz K, Carraway HE, Showel M, McDevitt MA, Gladstone D, Ghiaur G, Prince G, Seung AH, Benani D, Levis MJ, Karp JE, Smith BD. Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature. *Leuk Res*. 2017 Oct; 61:25-32. doi: 10.1016/j.leukres.2017.08.009. Epub 2017 Aug 30. Review. PubMed PMID: 28869816; PubMed Central PMCID: PMC5813685

141. Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, **Gore SD**, Gross CP, Ma X, Davidoff AJ. Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. *PLoS One*. 2017 Sep 13;12(9):e0184747. doi: 10.1371/journal.pone.0184747. eCollection 2017. PubMed PMID: 28902882; PubMed Central PMCID: PMC5597231.
142. Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, Platzbecker U, Gotze K, Vey N, Oliva E, Sugrue MM, Bally C, Kelaidi C, Al Ali N, Fenaux P, **Gore SD**, Komrokji R. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. *Oncotarget*. 2017 Jun 14;8(47):81926-81935. doi: 10.18632/oncotarget.18477. eCollection 2017 Oct 10. PubMed PMID: 29137233; PubMed Central PMCID: PMC5669859.
143. Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, **Gore SD**, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. *Blood*. 2018 Feb 15;131(7):818-821. doi: 10.1182/blood-2017-10-811729. Epub 2017 Dec 19. PubMed PMID: 29259002.
144. Stahl M, DeVeaux M, Fernández PM, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, **Gore SD**, Zeidan AM. Allogeneic hematopoietic cell transplantation following the use of hypomethylating agents among patients with relapsed or refractory AML: Findings from an international retrospective study. *Biol Blood Marrow Transplant*. 2018 Apr 9. pii: S1083-8791(18)30159-9. doi: 10.1016/j.bbmt.2018.03.025. [Epub ahead of print] PubMed PMID: 29649620.
145. Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, **Gore SD**, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK. Germline Tissues for Optimal Somatic Variant Detection in Myelodysplastic Syndromes (MDS). *Blood*. 2018 Apr 16. pii: blood-2018-01-827881.
146. Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, **Gore SD**, Zeidan AM. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey(). *Leuk Lymphoma*. 2018 Apr 18:1-4. doi: 0.1080/10428194.2018.1452219. [Epub ahead of print] PubMed PMID: 29667455.
147. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, **Gore SD**, Zeidan AM. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. *Blood Adv*. 2018 Apr 24;2(8):923-932. doi: 10.1182/bloodadvances.2018016121. PMID: 29685952
148. Amer M, Zeidan, Hanna A, Knaus, Tara M, Robinson, Andrea M.H, Towlerton, Edus H, Warren, Joshua F, Zeidner, Amanda L, Blackford, Amy Duffield, David Rizzieri, Mark Frattini, Moshe Yair Levy, Mark Schroeder, Anna Ferguson, Katherine Sheldon, Amy DeZern, Ivana Gojo, **Steven Gore**, Howard Streicher, Leo Luznik, and B. Douglas Smith. A multi-center Phase 1 trial of ipilimumab in myelodysplastic syndrome patients following hypomethylating agent failure. *Clin Cancer Res*. 2018 May 1. pii: clincanres.3763.2017. doi: 10.1158/1078-0432.CCR-17-3763. [Epub ahead of print]

PMID: 29716921

149. Amer M, Zeidan, Maximilian Stahl, Michelle DeVeaux, Smith Giri, Scott Huntington, Nikolai Podoltsev, Rong Wang, Xiaomei Ma, Amy J. Davidoff and **Steven D. Gore**. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: Are we using realistic estimates? *Blood Cancer Journal*, In Press, 2018.
150. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, **Gore SD**, Zeidan AM. Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. *Leuk Lymphoma*. 2018 Jul 2:1-4. doi: 10.1080/10428194.2018.1468893. [Epub ahead of print] No abstract available. PMID: 29963936
151. Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, **Gore SD**, Komrokji RS, Zeidan AM. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. *Blood Adv*. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414. PMID: 30037803
152. Ball B, Komrokji RS, Adès L, Sekeres MA, DeZern AE, Pleyer L, Vey N, Almeida A, Germing U, Cluzeau T, Platzbecker U, **Gore SD**, Fenaux P, Prebet T. Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. *Blood Adv*. 2018 Aug 28;2(16):2063-2071. doi: 10.1182/bloodadvances.2018015529. PMID: 30120104
153. Huntington SF, Hoag JR, Zhu W, Wang R, Zeidan AM, Giri S, Podoltsev NA, **Gore SD**, Ma X, Gross CP, Davidoff AJ. Oncologist Volume and Outcomes in Older Adults Diagnosed With Diffuse Large B Cell Lymphoma. *Cancer*. 2018 Sep 14. doi: 10.1002/cncr.31688. [Epub ahead of print]. PMID: 30216436
154. Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, **Gore SD**, Ma X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. *Blood Adv*. 2018 Oct 23;2(20):2681-2690. doi: 10.1182/bloodadvances.2018021436. PMID: 30333100
155. Chandhok NS, Boddu PC, **Gore SD**, Prebet T. What are the most promising new agents in myelodysplastic syndromes? *Curr Opin Hematol*. 2019 Jan 9. doi:10.1097/MOH.0000000000000483. [Epub ahead of print]. PMID: 30632987
156. Zeidan AM, **Gore SD**, Davidoff AJ. US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box. *J Clin Oncol*. 2017 Oct 1;35(28):3264. doi: 0.1200/JCO.2017.74.3104. Epub 2017 Aug 8. PubMed PMID: 28787256.
157. Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, **Gore SD**, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. *J Natl Compr Canc Netw*. 2019 Mar 1;17(3):211-219. doi: 10.6004/jnccn.2018.7095. PMID: 30865915

158. Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, **Gore SD**, Neparidze N, Ma X, Gross CP, Davidoff AJ, Huntington SF. Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States. *Cancer*. 2019 Aug 5. doi: 10.1002/cncr.32428. [Epub ahead of print]. PMID: 31381151
159. Huntington SF, Zhu W, Hoag JR, Wang R, Zeidan AM, Giri S, Podoltsev NA, **Gore SD**, Ma X, Gross CP, Davidoff AJ. Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma. *JNCI Cancer Spectr*. 2019 May 11;3(2):pkz030. doi: 10.1093/jncics/pkz030. eCollection 2019 Jun. PMID: 31360905
160. Coleman E, Panse G, Cowper S, Prebet T, **Gore S**, Leventhal J. Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease. *J Cutan Pathol*. 2019 Jun 29. doi: 10.1111/cup.13537. [Epub ahead of print]. PMID: 31254406
161. Zeidan AM, Podoltsev NA, Wang X, Bewersdorf JP, Shallis RM, Huntington SF, **Gore SD**, Davidoff AJ, Ma X, Wang R. Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis. *Cancer*. 2019 Sep 4. doi: 10.1002/cncr.32439. [Epub ahead of print]. PMID: 31483484.
162. Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, **Gore SD**, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. *Leuk Lymphoma*. 2019 Oct 1:1-12. doi: 10.1080/10428194.2019.1663423. [Epub ahead of print]. PMID: 31570040
163. Huntington SF, Hoag JR, Wang R, Zeidan AM, Giri S, **Gore SD**, Ma X, Gross CP, Davidoff AJ. Physician experience and risk of rituximab discontinuation in older adults with non-Hodgkin's lymphoma. *J Natl Compr Canc Netw*. 2019 Oct 1;17(10):1194-1202. doi: 10.6004/jnccn.2019.7314. PMID: 31590152
164. Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, **Gore SD**, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study. *Leuk Lymphoma*. 2019 Dec 26:1-10. doi: 10.1080/10428194.2019.1703970. [Epub ahead of print]. PMID: 31878809
165. Zeidner JF, Knaus HA, Zeidan AM, Blackford AL, Montiel-Esparza R, Hackl H, Prince GT, Gondek LP, Ghiaur G, Showel MM, DeZern AE, Pratz KW, Douglas Smith B, Levis MJ, **Gore S**, Coombs CC, Foster MC, Streicher H, Karp JE, Luznik L, Gojo I. Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. *Leukemia*. 2020 Jan 3. doi: 10.1038/s41375-019-0693-4. [Epub ahead of print]. PMID: 31900407
166. Pine AB, Chokr N, Stahl M, Steensma DP, Sekeres MA, Litzow MR, Luger SM, Stone RM, Greenberg PL, Bejar R, Bewersdorf JP, **Gore SD**, Zeidan AM. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. *Leuk Lymphoma*. 2020 Feb 6:1-10. doi: 10.1080/10428194.2020.1723013. [Epub ahead of print]. PMID: 32026740

167. Shallis RM, Patel TH, Podoltsev NA, Xu ML, Azar MM, **Gore SD**. Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia. *Leuk Res*. 2020 Jan 31;90:106315. doi: 10.1016/j.leukres.2020.106315. [Epub ahead of print] No abstract available. PMID: 32036123

Chapters, Books, and Reviews

168. Behrman, H.R., Hall, A.K., **Gore, S.D.**, et al. Paracrine Regulation of the corpus Luteum by purines, Prostaglandins and Peptides. In *Recent Advances in Fertility Research, Part A: Developments in Reproductive Endocrinology*, Muldoon, T.A., Mahesh, V.B., Perez-Ballester, eds. Alan R. Liss, Inc., New York, 1938, pp.321-238.
169. Abrams, R., and **Gore, S.D.** Chronic Infusion Catheters: An Oncologist's Perspective. *Percutaneous Intervention in the Venous System: with Clinical Perspectives*, Savader, S., and Trerotola, S., eds. Thieme Medical Publishers, New York, 1996, pp.262-265.
170. **Gore, S.D.** Acute Leukemia in Adults. In *Conn's Current Therapy*, Robert E. Rakel, ed. W.B. Saunders, Co, Philadelphia, PA, 1997.
171. Abrams, R.A., and **Gore, S.D.** Chronic Infusion Catheters: An Oncologist's Perspective. In *Percutaneous Intervention in the Venous System with Clinical Perspectives*, Savader, S. and Trerotola, S., eds. Thieme Medical publishers, New York, 2000, pp.386-389.
172. Saif, M.W., Hopkins, J.L., **Gore, S.D.** Autoimmune Phenomena in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. In *Leukemia and Lymphoma*, 2002, 43(11):2083-2092.
173. Deeg, H.J., Bowen, D., **Gore, S.D.**, Haferlach, T., Beau, M.M., Niemeyer, C. *Myelodysplastic Syndromes*, New York; Springer, 2006.
174. **Gore, S. D.**, Baylin, S.B., and Herman, J.G. Histone Deacetylase Inhibitors and Demethylating Agents. In *Pharmacology of Cancer Chemotherapy*, Lippincott Williams and Wilkins
175. Fandy, T.E., Carraway, H.E., and **Gore, S.D.** Modulating Gene Expression as a Therapeutic Approach in the Treatment of Acute Myeloid Leukemia. In *Acute Myelogenous Leukemia*, Judith E. Karp, ed. New Jersey: Humana, 2007, pp.275-291.
176. **Gore, S.D.**, Baylin, S.B., and Herman, J.G. Histone Deacetylase Inhibitors and Demethylating Agents. In *DeVita, Hellman, and Rosenberg's Cancer Principles & Practice of Oncology 8th E Edition*, Lippincott Williams & Wilkins, 2008, Section 11; pp.477-485, Volume 2.
177. Griffiths, E.A., **Gore, S.D.** DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes. In *Semin Hematol*, 2008, Jan; 45(1) pp.23-30.
178. **Gore, S.D.** New Agents for the Treatment of AML recent Study Findings. In *Clin Adv Hematol Oncol*, 2008, Nov; 6(11), pp.6-8. PMID: 19205109.
179. **Gore, S.D.**, Hermes-DeSantis, E.R. Future Directions in Myelodysplastic Syndrome: Newer Agents and the Role of Combination Approaches. In *Cancer Control*, 2008, Oct; 15 Suppl, pp40-49.
180. **Gore, S.D.**, Hermes-DeSantis, E.R. Enhancing Survival Outcomes in the Management of Patients with Higher-risk Myelodysplastic Syndromes. In *Cancer Control*, 2009, Oct; 16 Suppl, pp.2-10. PMID: 20010512
181. Emadi, A., **Gore, S.D.** Arsenic Trioxide – an Old Drug Rediscovered. In *Blood Reviews*, 2010, Jul-Sep; 24(4-5), pp.191-199. PMID: PMC2918685.
182. Loaiza-Bonilla, A., **Gore, S.D.**, Carraway, H.E. Novel Approaches for Myelodysplastic Syndromes: Beyond Hypomethylating Agents. In *Curr Opin Hematol*, 2010, Mar; 17(2),

- pp.104- 109. PMID: 20178141.
183. Carraway, H.D., **Gore, S.D.** Myelodysplastic Syndromes: Where Do We Go from Here? In *Oncology*, Williston Park, 2011, May; 25(6), pp.492-493. PMID: 21717903.
 184. Prebet, T., **Gore, S.D.** Treatment of Acute Promyelocytic Leukemia for Older Patients. In *J Natl Compre Canc Netw*, 2011, Mar; 9(3), pp3370342. PMID: 21393443
 185. **Gore, S.D.** New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome. In *Hematology*, Am Soc Hematol Educ Program, 2011, pp.550-555
 186. **Gore, S.D.** and Warlich, E. Myelodysplastic Syndromes. In *Leukemias Principles and Practice of Therapy, Part 2*, Wiley-Blackwell, 2011, pp 79.
 187. **Gore, S.D.**, Baylin, S.B., and Herman, J.G. Histone Deacetylase Inhibitors and Demethylating Agents. In DeVita, Hellman, and Rosenberg's *Cancer Principles & Practice of Oncology 8th Edition*, Lippincott Williams & Wilkins 9th Edition, 2011, pp.434-439.
 188. Griffiths, E.A., **Gore, S.D.** Epigenetic Therapies in MDS and AML. In *Adv Exp Med Biol*, 2013, 754, pp253-283. PMID: 22956506.
 189. Zeidan, A.M., Linhares, Y., **Gore, S.D.** Current Therapy of Myelodysplastic Syndromes. In *Blood Rev*, 2013, Jul 27. PMID: 23954262.
 190. Mitchell, M. **Gore, S.D.**, Zeidan, A.M. Iron Chelation Therapy in Myelodysplastic Syndromes: Where Do We Stand? In *Expert Rev Hematol*, 2013, Aug; 6(4), pp.397-410. PMID: 23991926.
 191. Deeg, H.J., Bowen, D., **Gore, S.D.**, Haferlach, T., Beau, M.M., Niemyer, C. Myelodysplastic Syndromes, In *Hematologic Malignancies*, 2nd edition, Springer, New York, NY, 2013, pp. 97-109.
 192. Kon Kim T, **Gore SD**, Zeidan AM. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions. *Semin Hematol*.2015 Jul; 52 (3): 172-83. PMID: 26111464
 193. Zeidan AM, **Gore SD**, Padron E, Komrokji RS. Current state of prognostication and risk stratification in myelodysplastic syndromes.*Curr Opin Hematol*. 2015 Mar;22(2):146-54. doi:10.1097/MOH.0000000000000110. Review. PMID: 25575032
 194. Nazha A, Sekeres MA, **Gore SD**, Zeidan AM. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise? *Oncologist*. 2015 Sep;20(9):1069-76. doi: 0.1634/theoncologist.2015-0067. Epub 2015 Jul 20. PMID:26194858
 195. Stahl M, **Gore SD**, Vey N, Prebet T. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. *Expert Opin Investig Drugs*. 2016 Mar;25(3):307-17. doi: 10.1517/13543784.2016.1146251. PMID: 26807602.
 196. Nazha A, Prebet T, **Gore S**, Zeidan AM. Chronic myelomonocytic leukemia: Are we finally solving the identity crisis? *Blood Rev*. 2016 Sep;30(5):381-8. doi: 10.1016/j.blre.2016.04.006. Epub 2016 Apr 25. Review. PMID: 27162201
 197. Ball B, Zeidan A, **Gore SD**, Prebet T. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. *Leuk Lymphoma*. 2017 May;58(5):1022-1036. doi: 10.1080/10428194.2016.1228927. Epub 2016 Sep 21. PMID: 27654579
 198. Stahl M, Kohrman N, **Gore SD**, Kim TK, Zeidan AM, Prebet T. Epigenetics in Cancer: A Hematological Perspective. *PLoS Genet*. 2016 Oct 10;12(10): e1006193. doi: 10.1371/journal.pgen.1006193. eCollection 2016 Oct. Review. PMID: 27723796

199. Podoltsev NA, Stahl M, Zeidan AM, **Gore SD**. Selecting initial treatment of acute myeloid leukaemia in older adults. *Blood Rev.* 2017 Mar;31(2):43-62. doi: 10.1016/j.blre.2016.09.005. Epub 2016 Oct 8. Review. PMID: 27745715
200. Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, **Gore SD**. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. *Cancer.* 2017 Oct 1;123(19):3662-3672. doi: 10.1002/cncr.30903. Epub 2017 Jul 31. Review. PubMed PMID: 28759108.
201. Zeidan AM, **Gore SD**, Davidoff AJ. US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box. *J Clin Oncol.* 2017 Oct 1;35(28):3264. doi: 0.1200/JCO.2017.74.3104. Epub 2017 Aug 8. PubMed PMID: 28787256.
202. Chandhok NS, Boddu PC, **Gore SD**, Prebet T. What are the most promising new agents in myelodysplastic syndromes? *Curr Opin Hematol.* 2019 Mar;26(2):77-87. doi: 10.1097/MOH.0000000000000483. PMID: 30632987
203. Sekeres MA, **Gore SD**, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC, Komrokji RS, Deeg HJ, Epling-Burnette PK. The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. *Leuk Lymphoma.* 2019 May 21:1-11. doi: 10.1080/10428194.2019.1616186. [Epub ahead of print]. PMID: 31111762
204. Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, **Gore SD**, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. *Leuk Lymphoma.* 2019 Jun 7:1-7. doi: 10.1080/10428194.2019.1622700. [Epub ahead of print]. PMID: 31170846

Invited Editorials and Commentaries

205. Griffiths E.A., **Gore, S.D.** MicroRNA: mlR-ly regulators of DNMT? *Blood*, 2009, Jun 18,113(25):6269-6270. No abstract available. PMID: 19541832.
206. **Gore, S.D.** In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment? *Leuk Res*, 2009, Dec; 33 Suppl 2: S2-6. PMID: 20004793
207. Suarez, L., and **Gore, S.D.** CpJeez! Az-a-natomy. *Blood*, 2012, Sep 20; 120(12):2354-2355. PMID: 22996655.
208. Griffiths, E.A., **Gore, S.D.** DNA methyltransferase inhibitors: class effect or unique agents? *Leuk Lymphoma*, 2013, 49:650-651.
209. Suarez, L., **Gore, S.D.** Demethylation demystification. *Blood*, 2013, Feb 28; 121(9):1488-1489. PMID: 23449614.
210. Norsworthy KJ, Cho E, Arora J, Kowalski J, Tsai HL, Warlick E, Showel M, Pratz KW, Sutherland LA, **Gore SD**, Ferguson A, Sakoian S, Greer J, Espinoza-Delgado I, Jones RJ, Matsui WH, Smith BD. Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies. *Leuk Res.* 2016 Oct;49:90-7. doi: 10.1016/j.leukres.2016.09.003. Epub 2016 Sep 3. PMID: 27619199
211. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study. Zeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev NA, Huntington SF, **Gore SD**, Davidoff

AJ. Cancer. 2017 Oct 1;123(19):3754-3762. doi: 10.1002/cncr.30814. Epub 2017 Jun 16.
PubMed PMID: 28621841

Practice Guidelines, Standards and Consensus Statements

212. Lo Coco, F., Zelent, A., Kimchi, A., Carducci, M., **Gore, S.D.**, Waxman, S. *Progress in D Differentiation Induction as a Treatment for Acute Promyelocytic Leukemia and Beyond*, Cancer Research, 2002, Oct 1; 62(19):5618-21. PMID: 12359776.
213. Zelent, A., Waxman, S., Carducci, M., Wright, J., Zweibel, J., **Gore, S.D.** *State of the translational science: summary of Baltimore workshop on gene re-expression as a therapeutic target in cancer*, Clin Cancer Res, January 2004, Jul 15;10(14)4622-9. PMID: 15269
214. Zelent, A., Petrie, K., Lotan, R., Waxman, S., **Gore, S.D.** *Clinical Translation of Epigenetics in Cancer: eN-CORE—a report on the second workshop*. Mol Cancer Ther, 2005, Nov;4(11):1810-9. PMID: 1626003
215. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Bowenber, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., deWitte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., **Gore, S.D.**, Schiffer, C.A., and Kantarjian, H. *Clinical Application and Proposal for Modification of the International Working Group (IWG) Response Criteria in Myelodysplasia*. Blood, 2006; 108:419-415.
216. Cheson, B.D., Bennett, J.M., Kantarjian, H., Pinto, A., Schiffer, C.A., Nimer, S.D., Lowenbert, B., Beran, M., deWitte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Wijermans, P.W., **Gore, S.D.**, and Greenbert, P.L. *Report of an International Working Group to Standardize Response Criteria for Myelodysplastic Syndromes*, Blood, 2006; 96:3671-2674.
217. Zelent, A., Petrie, K., Boix0Chornet, M., Melnick, A.M., Waxman, S., **Gore, S.D.** *Depression in the desert: the third workshop on clinical translation of epigenetics in cancer therapeutics*. Cancer Res, 2008, July 1;68(13):4967-70. PMID: 18593891.
218. Greenbert, P.L, Attar, E., Battiwalla, M., Bennett, J.M., Bloomfield, C.D., DeCastro, C.M., Deeg, H.J., Erba, H.P., Foran, J.M., Garcia-Manero, G., **Gore, S.D.**, Head, D., Maness, L.J., Millenson, M., Nimer, S D., O'Donnell, M.R., Saba, H, I., Shami, P.J., Spiers, K., Stone, R.M., Tallman, M.S., Westervelt, P. *Myelodysplastic Syndromes*. J Natl Compr Canc Netw, 2008, October;6(9):902-26. PMID: 18926100
219. Oliansky, D.M., Antin, J.H., Bennett, J.M., Deeg, H.J., Engelhardt, C., Hepinstall, K.V., deLima, M., **Gore, S.D.**, Potts, R.G., Silverman, L.R., Jones R.B., McCarthy, P.L., Jr., Hahn, T. *The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidenced-based review*. Biol Blood Marrow Transplant, 2009, May; 15(5):650. PMID: 19167676
220. Greenberg, P.L., Rigsby, C.K., Stone R.M., Deeg, H.J., **Gore, S.D.**, Millenson, M.M., Nimer, S.D., O'Donnell, M.R., Shami, P.J., Kumar, R. *NCCN Task Force: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes*. Journal of the National Comprehensive Cancer Network, 2009, Dec ;(7) Supp 9. PMID: 20064286.
221. Greenberg, P.L., Attar, E., Bennett, J.M., Bloomfield, C.D., DeCastro, C.M., Deeg, H.J., Foran, J.M., Gaensler, K., Garcia-Manero, G., **Gore, S.D.**, Head, D., Komrokji, R., Maness, L.J., Millensonm, M., Nimer, S.D., O'Donnell, M.R., Schroeder, M.A., Shami, P.J., Stone, R.M., Thompson, J.E., Westervelt, P. *NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes*. J Natl Comp Canc Netw, 2011, Jan; 9(1):30-56. PMID: 21233243.
222. Tallman, M.S., Lo-Coco, F., Kwaan, H.D., Sanz, M.A., **Gore, S.D.** *Clinical Roundtable Monograph. Early Death in Patients with Acute Promyelocytic Leukemia*. Hematology &

- Oncology, Feb 2011, Volume 9, Issue 2.
223. Greenberg, P.L., Attar, E., Bennett, J.M., Bloomfield, C.D., Borate, U., DeCastro, C.M., Deeg, H.J., Frankfurt, O., Gaensler, K., Garcia-Manero, G., **Gore, S.D.**, Head, D., Komrokji, R., Maness, L.J., Millenson, M., O'Donnell, M.R., Shami, P.J., Stein, B.L., Stone, R.M., Thompson, J.E., Westervelt, P., Wheeler, B., Shead, D.A., Naganuma, M. *Myelodysplastic Syndromes: Clinical Practice Guidelines in Oncology*. J Natl Compr Can Netw. 2013 Jul; 11(7):838-74. PMID: 23847220
224. Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, **Gore SD**, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, Lymphoma, and acute leukemia. J Immunother Cancer. 2016 Dec 20; 4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016. PMID: 28018601
225. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, **Gore SD**, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, Olin R, Peker D, Pollyea DA, Pratz K, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wang ES, Wieduwilt M, Gregory K, Ogba N. J Natl Compr Canc Netw. 2017 Jul;15(7):926-957. doi: 10.6004/jnccn.2017.0116. PMID: 28687581

Case Reports, Technical Notes, Letters

226. Zeidan, A., Faltas, B., Fricke, W., **Gore, S.D.**, Kettering, R., Sham, R. Sustained Remission in a patient with myelodysplastic syndrome and a complex karyotype after Erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma. *Leuk Lymphoma*, 2012, 54:1534-1537. PMID: 23098263.
227. Zeidan, A.M., Smith, B.D., Komrokji, R.S., **Gore, S.D.** Prognostication in Myelodysplastic Syndromes: Beyond the International Prognostic Scoring System (IPSS). In *Am J Med*, 2013, Apr; 126(4) e255. PMID: 23507216.
228. Zeidan, A.M., **Gore, S.D.**, Komrokji, R.S. Higher-risk Myelodysplastic Syndromes with del (5q): is Sequential Azacitidine-Lenalidomide Combination the Way to Go? In *Expert Rev Hematol*, 2013, Jun; 6(3), pp.251-254. PMID: 23782079.
229. Zeidan, A.M., **Gore, S.D.** Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation? *Expert Rev Hematol* 2013 Oct; 6(5):539-42. PMID: 24093972
230. Zeidan, A.M., Prebet, T., Saad, A.E., **Gore, S.D.** Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling? *Expert Rev Hematol* 2014 Apr; 7(2): 191-4. PMID: 24559255
231. Zeidan AM, **Gore SD** New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach. *Clin Cancer Res*. 2014 Oct 1; 20(19):4985-93. Doi: 10.1158/1078-0432.CCR-13-2725.
232. Lee EJ, Podoltsev N, Gore SD, Zeidan AM. The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions. *Blood Rev*. 2016 Jan;30(1):1-10. doi: 10.1016/j.clml.2015.07.637. Epub 2015 Jun 19. PMID: 26119927.
233. Kim TK, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K,

Stahl M, **Gore SD**, Zeidan AM. Single agent blinatumomab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. *Ann Hematol.* 2016 Oct;95(11):1895-8. doi: 10.1007/s00277-016-2761-4. Epub 2016 Jul 29. No abstract available. PMID: 27468851